var title_f29_45_30416="Dietary Reference Intakes";
var content_f29_45_30416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary Reference Intakes (DRIs): Recommended dietary allowances and adequate intakes of several vitamins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Life stage group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin A (&micro;g/d)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin C (mg/d)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin D (&micro;g/d)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin E (mg/d)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin K (&micro;g/d)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin B1 (Thiamine) (mg/d)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin B2 (Riboflavin) (mg/d)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin B3 (Niacin) (mg/d)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin B6 (Pyroxidine) (mg/d)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin B12 (Cobalamin) (&micro;g/d)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Folate (&micro;g/d)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"12\">",
"        Infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0 to 6 mo",
"       </td>",
"       <td>",
"        <em>",
"         400",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         40",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         10",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         4",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         2.0",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         0.2",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         0.3",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         2",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         0.1",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         0.4",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         65",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6 to 12 mo",
"       </td>",
"       <td>",
"        <em>",
"         500",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         50",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         10",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         5",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         2.5",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         0.3",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         0.4",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         4",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         0.3",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         0.5",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         80",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"12\">",
"        Children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-3 y",
"       </td>",
"       <td>",
"        <strong>",
"         300",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         6",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         30",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         0.5",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0.5",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0.5",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0.9",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         150",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-8 y",
"       </td>",
"       <td>",
"        <strong>",
"         400",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         25",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         7",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         55",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         0.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         8",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         200",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"12\">",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-13 y",
"       </td>",
"       <td>",
"        <strong>",
"         600",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         45",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         11",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         60",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         0.9",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0.9",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         12",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.0",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.8",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         300",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14-18 y",
"       </td>",
"       <td>",
"        <strong>",
"         900",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         75",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         75",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         16",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         400",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19-30 y",
"       </td>",
"       <td>",
"        <strong>",
"         900",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         90",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         120",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         16",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         400",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31-50 y",
"       </td>",
"       <td>",
"        <strong>",
"         900",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         90",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         120",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         16",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         400",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        51-70 y",
"       </td>",
"       <td>",
"        <strong>",
"         900",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         90",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         120",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         16",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.7",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.4*",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         400",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;70 y",
"       </td>",
"       <td>",
"        <strong>",
"         900",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         90",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         20",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         120",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         16",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.7",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.4*",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         400",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"12\">",
"        Females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-13 y",
"       </td>",
"       <td>",
"        <strong>",
"         600",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         45",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         11",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         60",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         0.9",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0.9",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         12",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.0",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.8",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         300",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14-18 y",
"       </td>",
"       <td>",
"        <strong>",
"         700",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         65",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         75",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.0",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.0",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         14",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         400",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19-30 y",
"       </td>",
"       <td>",
"        <strong>",
"         700",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         75",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         90",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         14",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         400",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31-50 y",
"       </td>",
"       <td>",
"        <strong>",
"         700",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         75",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         90",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         14",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         400",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        51-70 y",
"       </td>",
"       <td>",
"        <strong>",
"         700",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         75",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         90",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         14",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.5",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         400",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;70 y",
"       </td>",
"       <td>",
"        <strong>",
"         700",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         75",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         20",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         90",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         14",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.5",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         400",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"12\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14-18 y",
"       </td>",
"       <td>",
"        <strong>",
"         750",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         80",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         75",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         18",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.9",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         600",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19-30 y",
"       </td>",
"       <td>",
"        <strong>",
"         770",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         85",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         90",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         18",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.9",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         600",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31-50 y",
"       </td>",
"       <td>",
"        <strong>",
"         770",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         85",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         90",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         18",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.9",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         600",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"12\">",
"        Lactation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14-18 y",
"       </td>",
"       <td>",
"        <strong>",
"         1200",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         115",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         19",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         75",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         17",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.0",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.8",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         500",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19-30 y",
"       </td>",
"       <td>",
"        <strong>",
"         1300",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         120",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         19",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         90",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         17",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.0",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.8",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         500",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31-50 y",
"       </td>",
"       <td>",
"        <strong>",
"         1300",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         120",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         19",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         90",
"        </em>",
"       </td>",
"       <td>",
"        <strong>",
"         1.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         17",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.0",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2.8",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         500",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table presents Recommended Dietary Allowances (RDAs) in bold type and Adequate Intakes (AIs) in italic type. An RDA is the average daily dietary intake level; sufficient to meet the nutrient requirements of nearly all healthy individuals in a group. It is calculated from an Estimated Average Requirement (EAR). If sufficient scientific evidence is not available to establish an EAR, and thus calculate an RDA, an AI is usually developed.",
"    <div class=\"footnotes\">",
"     * Because 10 to 30 percent of older people may malabsorb food-bound B12, it is advisable for those older than 50 years to meet their RDA mainly by consuming foods fortified with B12 or a supplement containing B12.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Otten JJ, Hellwig JP, Meyers LD (Eds), The National Academies Press, Washington, DC 2006. pp.530-541. Copyright &copy; 2006, National Academy of Sciences.",
"     <br>",
"      Sources: Dietary reference intakes for Thiamin, Riboflavin, Niacin, Vitamin B",
"      <sub>",
"       6",
"      </sub>",
"      , Folate, Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      , Panthothenic acid, Biotin, and Choline (1998); Dietary reference intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids (2000). These reports may be accessed via",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       www.nap.edu",
"      </a>",
"      .",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30416=[""].join("\n");
var outline_f29_45_30416=null;
var title_f29_45_30417="Chest radiograph of a child with pneumomediastinum";
var content_f29_45_30417=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of a child with pneumomediastinum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this radiograph of a child with pneumomediastinum, the following characteristic signs are seen: 1) The \"continuous diaphragm sign\", in which the mediastinal gas is seen as a thin lucent line outlining the superior surface of the diaphragm and separating it from the heart (white arrows). 2) \"Naclerio's V sign\", in which the gas outlines the lateral margin of the descending aorta and extends laterally over left hemidiaphragm (black arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ibrahim Janahi and Ammar Saadoon.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30417=[""].join("\n");
var outline_f29_45_30417=null;
var title_f29_45_30418="Exogenous mold endophthalmitis";
var content_f29_45_30418=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Exogenous mold endophthalmitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Exogenous mold endophthalmitis following eye trauma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marlene Durand, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30418=[""].join("\n");
var outline_f29_45_30418=null;
var title_f29_45_30419="Escharotomies dorsal hand";
var content_f29_45_30419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Escharotomies of the burned hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Escharotomies have been made in the dorsal right hand to release the constriction and restore blood flow to the hand and digits. The longitudinal full thickness incisions are made in the intermetacarpal spaces, avoiding exposure of the tendons and joints. The radial and ulnar incisions are carried proximally onto the wrist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30419=[""].join("\n");
var outline_f29_45_30419=null;
var title_f29_45_30420="EtCO2 wave interpretation b";
var content_f29_45_30420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Capnographic airway assessment for procedural sedation and analgesia, continued",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 666px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Varying waveform amplitutde and width.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Depending on duration and severity of bronchospasm.",
"      <br>",
"       &Delta; Depending on duration of episode.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Krauss, B, Hess, DR. Capnography for Procedural Sedation and Analgesia in the Emergency Department. Annals of Emergency Medicine 2007; 50:172. Copyright &copy; 2007 The American College of Emergency Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30420=[""].join("\n");
var outline_f29_45_30420=null;
var title_f29_45_30421="Porphyria cutanea tarda and hepatitis C virus infection";
var content_f29_45_30421=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Porphyria cutanea tarda and hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30421/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30421/contributors\">",
"     Steven Flamm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30421/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30421/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30421/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30421/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30421/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/45/30421/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porphyria cutanea tarda (PCT) is the most common of the hepatic porphyrias. It is due to reduced activity of the enzyme uroporphyrinogen decarboxylase (UROD), causing the subsequent build-up of uroporphyrinogen in the blood and urine (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/1\">",
"     1",
"    </a>",
"    ]. PCT has both sporadic and inherited (autosomal dominant) forms that are indistinguishable clinically. Hepatic UROD enzyme activity is diminished in both disorders. However, erythrocyte UROD activity levels are reduced only in the inherited form [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of PCT and the etiologic relation of the sporadic form to hepatitis C virus (HCV) infection will be reviewed here. General characteristics of PCT and the inherited porphyrias, including diagnosis and treatment, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin and the liver are the two main sites affected in sporadic PCT as the classic presentation consists of photosensitivity and uroporphyrinuria in the setting of chronic liver disease. Several observations support the hypothesis that environmental triggers are necessary to provoke an attack of PCT. When families of patients with inherited PCT have been studied, for example, first-degree relatives often have decreased uroporphyrinogen decarboxylase (UROD) activity despite having no symptoms of PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with sporadic PCT, on the other hand, may have normal UROD activity in between attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/3\">",
"     3",
"    </a>",
"    ]. Possible triggers of PCT include polyhalogenated hydrocarbons (such as hexachlorobenzene), alcohol, estrogens, and iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H4527402#H4527402\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Etiology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin lesions are frequently the reason that patients with either form of PCT first seek medical attention. Exposure to the sun",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    minor trauma can lead to skin erythema and the development of vesicles and bullae that may become hemorrhagic. Hyperpigmentation, hypopigmentation, hirsutism, and sclerodermatous changes may develop with the passage of time (",
"    <a class=\"graphic graphic_picture graphicRef74528 \" href=\"UTD.htm?13/30/13794\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic liver disease is common in sporadic PCT. Liver biopsy shows a wide range of changes, including steatosis, mild to severe inflammation, hepatic fibrosis, and cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/9\">",
"     9",
"    </a>",
"    ]. Hepatocellular carcinoma, usually in the presence of cirrhosis, also occurs with increased frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, liver involvement appears to be infrequent in inherited PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/11\">",
"     11",
"    </a>",
"    ]. One small study, for example, found no liver disease in five such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For many years, alcohol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    iron were thought to be responsible for the hepatic abnormalities. Many patients with sporadic PCT drink excessive amounts of alcohol and have elevated plasma aminotransferase levels. Most patients (about 80 percent) also have mild degrees of iron overload that was thought to be due to the defect in heme synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, direct effects of HCV and mutations in the HFE gene that are responsible for hereditary hemochromatosis are thought to be more important factors in the genesis of the iron overload. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pathogenesis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H5#H5\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Porphyria cutanea tarda'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients, however, have neither excess alcohol intake nor iron overload, indicating an important pathogenetic role for some other factor. One such factor may be HCV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H4527395#H4527395\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Susceptibility factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RELATIONSHIP TO HEPATITIS C VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A strong association between the sporadic form of PCT and HCV infection has been demonstrated in multiple studies. A systematic review of 50 studies that included a total of 2167 patients with PCT found an overall prevalence of HCV of 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/14\">",
"     14",
"    </a>",
"    ]. However, there was marked geographic variability; lowest prevalence rates (20 to 30 percent) were observed in reports from Australia, the Czech Republic and France, while the highest rates (71 to 85 percent) were observed in Japan, Italy and Spain. The prevalence in North America was 66 percent. A central factor in the geographic variability appeared to be the baseline rates of HCV infection in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which HCV infection might cause or act as a trigger for PCT in predisposed subjects is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/15\">",
"     15",
"    </a>",
"    ]. It has been suggested that HCV, a cytopathic virus, is able to decompartmentalize iron from within the hepatocyte, leading to the release of \"free\" iron. This iron may uncouple the cytochrome P450",
"    <span class=\"nowrap\">",
"     reductase/cytochrome",
"    </span>",
"    P450 system, resulting in the release of activated oxygen which may decrease uroporphyrinogen decarboxylase (UROD) activity and provoke an attack [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic HCV infection may impair porphyrin metabolism by reducing the glutathione concentration in hepatic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/18\">",
"     18",
"    </a>",
"    ]. The lack of glutathione may decrease the ability to reduce oxidized uroporphyrins; accumulation of these compounds may exert an inhibitory effect on UROD.",
"   </p>",
"   <p>",
"    Another contributing factor to liver siderosis in some patients with PCT is a mutation in the HFE gene, the gene that is responsible for hereditary hemochromatosis via increased intestinal iron absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    .) The frequency of interaction between the HFE mutation and HCV infection was illustrated in a series of 108 patients with PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/20\">",
"     20",
"    </a>",
"    ]. Compared to normal controls, the patients were more likely to be homozygous for C282Y (19 versus 0.5 percent), compound heterozygotes (7 versus less than 1 percent), and be HCV infected (59 versus 2 percent). In addition, almost one-half of the patients consumed more than 70 g of alcohol per day, which may also have contributed to the iron overload. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H5#H5\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Porphyria cutanea tarda'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PCT is discussed in detail separately, but will be briefly reviewed here. PCT is typically suspected on clinical grounds and the diagnosis is confirmed by the demonstration of markedly elevated urine uroporphyrin levels. Values of urinary porphyrins &gt;800",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    are often seen when photosensitivity is present, well above the normal range of 10 to 50",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/22\">",
"     22",
"    </a>",
"    ]. The diagnosis can also be made directly by measuring hepatic uroporphyrinogen decarboxylase (UROD) activity (if available). Erythrocyte UROD activity can also be measured if the inherited form of PCT is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H4527425#H4527425\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional diagnostic testing is important in PCT, because factors that contribute to the disease may themselves require attention. It is therefore important to screen for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV infection",
"     </li>",
"     <li>",
"      Hepatitis C virus infection. HCV serological testing (HCV antibody by RIBA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      HCV RNA by PCR) should be performed and other forms of liver disease excluded. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"       \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Studies for the presence of iron overload and genetic testing for HFE mutations. If positive, family members should be screened appropriately [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30421/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"       \"Pathophysiology and diagnosis of iron overload syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link\">",
"       \"Genetics of hereditary hemochromatosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of PCT has traditionally consisted of three separate approaches:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoiding factors that precipitate attacks, such as alcohol, estrogens, and exposure to polyhalogenated hydrocarbons. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H4527395#H4527395\">",
"       \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Susceptibility factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of the underlying iron overload state, if present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of hereditary hemochromatosis\", section on 'Phlebotomy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H4527453#H4527453\">",
"       \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Repeated phlebotomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of HCV infection, if present (see below). PCT should be considered an indication for treatment of HCV. Thus, treatment should be considered even in patients with HCV and PCT who have only mild liver disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our experience has been that PCT may improve with suppression of HCV RNA even if patients do not achieve a sustained virologic response. Our approach to such patients has been to treat them with a maintenance dose of peginterferon in the hope to achieve suppression of HCV RNA and thereby control the PCT, although this approach has not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A strong association between the sporadic form of porphyria cutanea tarda (PCT) and hepatitis C virus (HCV) infection has been demonstrated in multiple studies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Relationship to hepatitis C virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic presentation consists of photosensitivity and uroporphyrinuria in the setting of chronic liver disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is confirmed by the demonstration of markedly elevated urine uroporphyrin levels. Values of urinary porphyrins &gt;800",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      are often seen when photosensitivity is present, well above the normal range of 10 to 50",
"      <span class=\"nowrap\">",
"       mcg/day.",
"      </span>",
"      The diagnosis can also be made directly by measuring hepatic uroporphyrinogen decarboxylase activity (if available). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should also undergo testing for HCV infection (and exclusion of other forms of liver disease), HIV infection, and iron overload. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are three major considerations for treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoiding factors that precipitate attacks, such as alcohol, estrogens, and exposure to polyhalogenated hydrocarbons. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H4527395#H4527395\">",
"       \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Susceptibility factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of the underlying iron overload state, if present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of hereditary hemochromatosis\", section on 'Phlebotomy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H4527453#H4527453\">",
"       \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Repeated phlebotomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of HCV infection, if present. We suggest that treatment of patients with HCV and PCT be based upon the same considerations as treatment of patients with chronic HCV without PCT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"       \"Overview of the management of chronic hepatitis C virus infection\"",
"      </a>",
"      .) In addition, PCT should be considered an indication for treatment of HCV in patients who are otherwise candidates; thus, treatment should be considered even in patients with HCV and PCT who have only mild liver disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our experience has been that PCT may improve with suppression of HCV RNA even if patients do not achieve a sustained virologic response. Our approach to such patients has been to treat them with a maintenance dose of peginterferon in the hope to achieve suppression of HCV RNA and thereby control the PCT, although this approach has not been studied.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/1\">",
"      Kushner JP, Barbuto AJ, Lee GR. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J Clin Invest 1976; 58:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/2\">",
"      Elder GH, Sheppard DM, Tovey JA, Urquhart AJ. Immunoreactive uroporphyrinogen decarboxylase in porphyria cutanea tarda. Lancet 1983; 1:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/3\">",
"      de Verneuil H, Aitken G, Nordmann Y. Familial and sporadic porphyria cutanea: two different diseases. Hum Genet 1978; 44:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/4\">",
"      CAN C, NIGOGOSYAN G. Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. Report of 348 cases caused by this fungicide. JAMA 1963; 183:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/5\">",
"      Cripps DJ, Peters HA, Gocmen A, Dogramici I. Porphyria turcica due to hexachlorobenzene: a 20 to 30 year follow-up study on 204 patients. Br J Dermatol 1984; 111:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/6\">",
"      Cripps DJ. Diet and alcohol effects on the manifestation of hepatic porphyrias. Fed Proc 1987; 46:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/7\">",
"      Haberman HF, Rosenberg F, Menon IA. Porphyria cutanea tarda: comparison of cases precipitated by alcohol and estrogens. Can Med Assoc J 1975; 113:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/8\">",
"      Grossman ME, Bickers DR, Poh-Fitzpatrick MB, et al. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. Am J Med 1979; 67:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/9\">",
"      Di Padova C, Marchesi L, Cainelli T, et al. Effects of phlebotomy on urinary porphyrin pattern and liver histology in patients with porphyria cutanea tarda. Am J Med Sci 1983; 285:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/10\">",
"      Siersema PD, ten Kate FJ, Mulder PG, Wilson JH. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver 1992; 12:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/11\">",
"      de Verneuil H, Nordmann Y, Phung N, et al. Familial and sporadic porphyria cutanea: two different diseases.. Int J Biochem 1978; 9:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/12\">",
"      Herrero C, Vicente A, Bruguera M, et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993; 341:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/13\">",
"      Felsher BF, Jones ML, Redeker AG. Iron and hepatic uroporphyrin synthesis. Relation in porphyria cutanea tarda. JAMA 1973; 226:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/14\">",
"      Gisbert JP, Garc&iacute;a-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003; 39:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/15\">",
"      Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/16\">",
"      Sinclair PR, Bement WJ, Bonkovsky HL, Sinclair JF. Inhibition of uroporphyrinogen decarboxylase by halogenated biphenyls in chick hepatocyte cultures. Essential role for induction of cytochrome P-448. Biochem J 1984; 222:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/17\">",
"      Smith AG, Francis JE. Chemically-induced formation of an inhibitor of hepatic uroporphyrinogen decarboxylase in inbred mice with iron overload. Biochem J 1987; 246:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/18\">",
"      Suarez M, Beloqui O, Ferrer J, et al. Glutation reducido linfocitazio y hepatitis cronica activa por virus C. Gastroenterol Hepatol 1992; 15:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/19\">",
"      Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/20\">",
"      Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000; 95:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30421/abstract/21\">",
"      Roberts AG, Whatley SD, Morgan RR, et al. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349:321.",
"     </a>",
"    </li>",
"    <li>",
"     Bissel DM. Haem metabolism and the porphyrias. In: Liver and Biliary Disease, Wright R, Millward-Sadler GH, Alberti KG, Karran S (Eds), Saunders, Philadelphia 1985. p.398.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3657 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-99A7E1262A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30421=[""].join("\n");
var outline_f29_45_30421=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RELATIONSHIP TO HEPATITIS C VIRUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3657\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3657|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/31/25077\" title=\"figure 1\">",
"      Heme synthesis and porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3657|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/30/13794\" title=\"picture 1\">",
"      Porphyria cutanea tarda",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=related_link\">",
"      Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_45_30422="Pathogenesis of diabetic retinopathy";
var content_f29_45_30422=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of diabetic retinopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30422/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30422/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30422/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30422/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30422/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30422/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30422/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/45/30422/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinopathy is a major cause of morbidity in patients with type 1 and 2 diabetes. The incidence of blindness, for example, is 25 times higher in patients with diabetes than in the general population. Furthermore, diabetic retinopathy (DR) is the most common cause of blindness in middle-aged subjects, accounting for at least 12,000 new cases in the United States each year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/1\">",
"     1",
"    </a>",
"    ]. Visual loss from diabetic retinopathy may be secondary to macular edema (retinal thickening and edema involving the macula), hemorrhage from new vessels, retinal detachment, or neovascular glaucoma.",
"   </p>",
"   <p>",
"    The pathogenesis of DR is multifactorial but is primarily caused by the metabolic effects of chronic hyperglycemia, which result in vascular changes and subsequent retinal injury and ischemia. More advanced retinal disease, including proliferative vascular changes and neovascularization in the setting of retinal ischemia, may be mediated by other mechanisms such as the action of vasoactive substances released during the inflammatory process.",
"   </p>",
"   <p>",
"    The pathogenesis of DR is reviewed here. Issues related to screening and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42501?source=see_link\">",
"     \"Screening for diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36023?source=see_link\">",
"     \"Classification and clinical features of diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=see_link\">",
"     \"Prevention and treatment of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chronic hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hyperglycemia is thought to be the primary cause of diabetic retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/2\">",
"     2",
"    </a>",
"    ]. Evidence in support for this hypothesis has come from the Diabetes Control and Complications Trial (DCCT), which found that intensive insulin therapy, achieving a mean hemoglobin A1C (A1C) of 7.9 percent, reduced the incidence of new cases of retinopathy by as much as 76 percent compared with conventional therapy. The reduction was directly related to the degree of glycemic control as estimated from hemoglobin A1C values (mean A1C with conventional therapy was approximately 9.9 percent); progressive retinopathy was uncommon in patients with A1C values below 7 percent (",
"    <a class=\"graphic graphic_figure graphicRef82664 \" href=\"UTD.htm?42/55/43901\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United Kingdom Prospective Diabetes Study found similar results in patients with type 2 diabetes; each 1 percent point reduction in A1C was associated with a 37 percent reduction in development of retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While chronic hyperglycemia is the fundamental prerequisite for diabetic retinopathy, much of current research has focused on the hemodynamic, biochemical, and hormonal mechanisms involved in the pathogenesis of this disease process, in an effort to develop new therapeutic targets [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Three of the main mechanisms are: impaired autoregulation of retinal blood flow, accumulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    within retinal cells, and accumulation of advanced glycosylation end products in the extracellular fluid. A more detailed discussion of this can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link&amp;anchor=H2#H2\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data supporting these mechanisms primarily refer to the induction of retinal injury. More advanced retinal disease, including proliferative vascular changes and neovascularization in the setting of retinal ischemia, may be mediated by other mechanisms such as the action of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Autoregulation of retinal blood flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hyperglycemia may increase retinal blood flow. Retinal blood flow is constant until the mean arterial pressure is raised about 40 percent above baseline. However, this autoregulatory mechanism is impaired in the presence of hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/4\">",
"     4",
"    </a>",
"    ]. The ensuing increase in retinal blood flow causes increased shear stress on the retinal blood vessels, which may be a stimulus for the production of vasoactive substances, vascular leakage, and increased fluid accumulation in the outer layers of the retina, resulting in macular edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Sorbitol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose that enters cells is metabolized in part to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    via the enzyme aldose reductase; sorbitol is then metabolized to fructose, a process that is relatively slow (",
"    <a class=\"graphic graphic_figure graphicRef81926 \" href=\"UTD.htm?7/24/7565\">",
"     figure 2",
"    </a>",
"    ). The role of sorbitol production and accumulation in the pathogenesis of diabetic retinopathy is uncertain. The observation that a polymorphism near the transcription site of the aldose reductase gene is associated with the early onset of retinopathy in some patients with type 2 diabetes is compatible with a potential pathogenetic role for this pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consumption of NADPH during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    production can lead to oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/8\">",
"     8",
"    </a>",
"    ], and subsequent sorbitol accumulation can result in altered",
"    <span class=\"nowrap\">",
"     Na/K-ATPase",
"    </span>",
"    activity, impaired phosphatidylinositol metabolism, increased prostaglandin production, and alterations in the activity of protein kinase C isoforms. Protein kinase C is important in the pathogenesis of retinopathy because it may mediate the activity of VEGF as well as regulate vascular permeability, and it may further cause the accumulation of sorbitol [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13000?source=see_link&amp;anchor=H3#H3\">",
"     \"Aldose reductase inhibitors in the prevention of diabetic complications\", section on 'Sorbitol accumulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     Sorbitol",
"    </a>",
"    accumulation within the cells of the lens is more pronounced with chronic hyperglycemia. It leads to a rise in intracellular osmolality (which causes movement of water into the cells and cell swelling) and to a decrease in intracellular myoinositol, both of which can interfere with cell metabolism. Sorbitol accumulation may also be important in the cataract formation induced by hyperglycemia because swelling of lens fiber cells can lead to their rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Advanced glycosylation end products",
"    </span>",
"    &nbsp;&mdash;&nbsp;In chronic hyperglycemia, some of the excess glucose combines with free amino acids or serum or tissue proteins. This nonenzymatic process initially forms reversible early glycosylation products and later irreversible advanced glycosylation end products (AGEs) via an Amadori rearrangement (",
"    <a class=\"graphic graphic_figure graphicRef80716 \" href=\"UTD.htm?22/4/22606\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/11\">",
"     11",
"    </a>",
"    ]. Serum AGE concentrations are high in diabetic patients, a change that can lead to tissue accumulation of AGEs, which may cross link with collagen, thereby initiating microvascular complications. AGE accumulation has also been implicated in cataract formation.",
"   </p>",
"   <p>",
"    In addition, the interaction between AGEs and their receptor (RAGE) generates reactive oxygen species (ROS) and subsequently vascular inflammation. Reactive oxygen species have been shown to be elevated in the vitreous fluid of patients with proliferative diabetic retinopathy (PDR), with a correlation between increasing levels of ROS and more advanced PDR [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/12\">",
"     12",
"    </a>",
"    ]. There is also evidence that inhibition of the renin-angiotensin system with an angiotensin II receptor blocker (ARB) in vitro can inhibit AGE-evoked inflammatory reactions in endothelial cells by suppressing ROS generation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Retinal microthrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of retinal microthrombosis has long been suspected in diabetic patients (on the basis of animal models of diabetes), and one postmortem study demonstrated the presence of microthromboses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/14\">",
"     14",
"    </a>",
"    ]. In this study, the retinal vascular network of nine diabetic patients (average duration of diabetes six years) contained more and larger platelet-fibrin thrombi, as compared with eight age-matched nondiabetic subjects.",
"   </p>",
"   <p>",
"    Microthrombosis leads to the occlusion of retinal capillaries and capillary leakage. Increased adhesion of leukocytes to retinal vascular endothelium is one of the earliest changes observed in the retina before the onset of clinically detectable diabetic retinopathy, and may be involved in increased vascular permeability. A loss of endothelial integrity leads to retinal ischemia, with subsequent release of growth factors such as IGF-1, platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and VEGF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth factors promote the growth of new blood vessels from adjacent vessels in an abortive attempt to revascularize the diseased tissue. Studies in experimental models of retinopathy have shown that neovascularization is mediated in part by the interaction between IGF-1 and VEGF. In one animal model of retinopathy, as an example, an IGF-1 receptor antagonist reduced the degree of retinal revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/15\">",
"     15",
"    </a>",
"    ]. The possible role of IGF-1 is supported by the clinical observations that retinopathy often worsens in the first year after the onset of intensive insulin therapy (",
"    <a class=\"graphic graphic_figure graphicRef61305 \" href=\"UTD.htm?28/32/29197\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], which may increase serum IGF-1 concentrations, and can be reversed by pituitary injury or hypophysectomy, which lowers serum IGF-1 concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VEGF is produced by many retinal cell types in response to hypoxia. In retinas from diabetic patients, the intensity of immunostaining for VEGF is proportional to the severity of the retinopathy, and vitreous fluid VEGF concentrations are increased [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. VEGF promotes growth of new blood vessels, and may increase vascular permeability.",
"   </p>",
"   <p>",
"    Erythropoietin has also been identified as a likely factor promoting retinal angiogenesis in diabetic retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Concentrations of erythropoietin and VEGF were elevated in the vitreous fluid of 73 patients with PDR compared with 71 patients without diabetes (erythropoietin concentration 464.0 versus 36.5 mIU per mL, respectively). Erythropoietin was more strongly correlated with retinopathy than VEGF. Blockade of erythropoietin inhibited endothelial-cell proliferation in vitro and inhibited retinal neovascularization in vivo in a mouse model. Elevated erythropoietin levels have also been identified in patients with diabetic macular edema who did not have retinal ischemia or proliferative retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other growth factors may contribute to progression of the retinal disease, including basic fibroblast growth factor (bFGF) and hepatocyte growth factor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/20,25\">",
"     20,25",
"    </a>",
"    ]. In one study, as an example, the local concentration of bFGF was much higher in patients with active proliferative retinopathy as compared to those in whom the retinopathy had regressed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Carbonic anhydrase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbonic anhydrase concentrations were elevated in the vitreous from individuals with PDR compared with diabetics without retinopathy and nondiabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, intravitreal carbonic anhydrase injections increased retinal vascular permeability with equal potency to VEGF, through a pH-mediated activation of bradykinin, a vasoactive substance. Furthermore, injection of both carbonic anhydrase and VEGF produced additive increases in vascular permeability. Thus, carbonic anhydrase appears to play a major role in retinal vascular permeability in PDR and may be a target for future therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic influences affect the severity of retinopathy. In 372 patients in the DCCT (who had 467 first-degree relatives with diabetes), severe retinopathy was three times more frequent among the relatives of the retinopathy-positive patients than the retinopathy-negative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How genetic factors might affect the development of retinopathy is not well understood. One possibility is polymorphisms in the platelet membrane glycoprotein",
"    <span class=\"nowrap\">",
"     Ia/IIa",
"    </span>",
"    (alpha-2, beta-1 integrin) receptor for collagen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .) In a case control study, patients with type 2 diabetes who were homozygous for the Bgl II polymorphism had a significantly increased risk of retinopathy (odds ratio 3.4) as compared with those lacking this polymorphism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/28\">",
"     28",
"    </a>",
"    ]. Platelets with this polymorphism may interact with glycosylated collagen more easily than those lacking it, leading to more rapid retinal vascular injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ethnic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic susceptibility to retinopathy is also suggested by the finding in some studies of a greater prevalence of retinopathy among certain ethnic groups. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 105 patients with type 2 diabetes who were followed for four years, retinopathy occurred more often among blacks than whites (50 versus 19 percent); the difference could not be explained by other factors such as A1C values, systolic blood pressure, or gender [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Veterans Affairs Diabetes Trial, the prevalence of moderate to severe diabetic retinopathy was found to be higher for Hispanics and African-Americans than for non-Hispanic whites (36, 29, and 22 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/30\">",
"       30",
"      </a>",
"      ]. The differences were not accounted for by other factors (age, duration of diabetes, A1C, blood pressure).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, ethnicity did not explain the difference in prevalence of retinopathy in a cross-sectional study of 778 diabetic patients age 45 to 85 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/31\">",
"     31",
"    </a>",
"    ]. Although there was a higher prevalence of retinopathy, as well as macular edema, in blacks (36.5 and 11.1 percent) and Hispanics (37.4 and 10.7 percent) compared with whites (24.8 and 2.7 percent), race was not an independent predictor of retinopathy; longer duration of diabetes, higher fasting glucose, greater waist-hip ratio, and use of insulin or oral hypoglycemic medications were independent predictors of diabetic eye disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been case reports of macular edema occurring in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , though its incidence is unknown. Patients who are at risk for fluid retention or who have heart or renal insufficiency appear to be at greatest risk. Thiazolidinediones should be discontinued in patients who develop macular edema [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Relation to nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between the development of DR and nephropathy, independent of the degree of hyperglycemia and the duration of diabetes, suggests that common pathogenetic factors may underlie the development of both complications. One study evaluated the correlation between albuminuria and retinopathy in 815 patients with type 2 diabetes (144 Hispanics and 671 whites) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30422/abstract/34\">",
"     34",
"    </a>",
"    ]. The presence of albuminuria, defined as urinary albumin excretion &gt;200",
"    <span class=\"nowrap\">",
"     mcg/min,",
"    </span>",
"    was a significant predictor for retinopathy (as detected via stereoscopic retinal fundus photographs) among the Hispanic (odds ratio 11.1) but not the white patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic retinopathy (DR) is a major cause of morbidity in patients with type 1 and type 2 diabetes. The development of DR is complex and is the result of many interrelated factors, which cause two basic changes within the retinal vessels, namely: abnormal permeability, and vascular occlusion with ischemia and subsequent neovascularization.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic hyperglycemia is thought to be the primary cause of DR. Both the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study have found that glycemic control reduces the incidence of new cases of retinopathy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperglycemia can cause retinal injury through several possible mechanisms. Three of the main hypotheses for the pathogenesis of DR are: impaired autoregulation of retinal blood flow, accumulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"       sorbitol",
"      </a>",
"      within retinal cells, and accumulation of advanced glycosylation end products in the extracellular fluid. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More advanced retinal disease, including proliferative vascular changes and neovascularization in the setting of retinal ischemia, may be mediated by other mechanisms such as the action of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Growth factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention. 2003 National Diabetes Fact Sheet. file://www.cdc.gov/diabetes/pubs/estimates.htm#complications (Accessed on March 28, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/2\">",
"      Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/3\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/4\">",
"      Kohner EM, Patel V, Rassam SM. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 1995; 44:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/5\">",
"      Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/6\">",
"      Ruberte J, Ayuso E, Navarro M, et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest 2004; 113:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/7\">",
"      Ko BC, Lam KS, Wat NM, Chung SS. An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 1995; 44:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/8\">",
"      Nyengaard JR, Ido Y, Kilo C, Williamson JR. Interactions between hyperglycemia and hypoxia: implications for diabetic retinopathy. Diabetes 2004; 53:2931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/9\">",
"      Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/10\">",
"      Lee AY, Chung SK, Chung SS. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci U S A 1995; 92:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/11\">",
"      Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994; 43:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/12\">",
"      Yeh PT, Yang CM, Huang JS, et al. Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy. Ophthalmology 2008; 115:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/13\">",
"      Yamagishi S, Matsui T, Nakamura K, et al. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res 2008; 40:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/14\">",
"      Boeri D, Maiello M, Lorenzi M. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 2001; 50:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/15\">",
"      Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/16\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/17\">",
"      Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/18\">",
"      Sharp PS, Fallon TJ, Brazier OJ, et al. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 1987; 30:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/19\">",
"      Boulton M, Foreman D, Williams G, McLeod D. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998; 82:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/20\">",
"      Katsura Y, Okano T, Noritake M, et al. Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders. Diabetes Care 1998; 21:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/21\">",
"      Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/22\">",
"      Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005; 353:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/23\">",
"      Katsura Y, Okano T, Matsuno K, et al. Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetes Care 2005; 28:2252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/24\">",
"      Hern&aacute;ndez C, Fonollosa A, Garc&iacute;a-Ram&iacute;rez M, et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care 2006; 29:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/25\">",
"      Sivalingam A, Kenney J, Brown GC, et al. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990; 108:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/26\">",
"      Gao BB, Clermont A, Rook S, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007; 13:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/27\">",
"      Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/28\">",
"      Matsubara Y, Murata M, Maruyama T, et al. Association between diabetic retinopathy and genetic variations in alpha2beta1 integrin, a platelet receptor for collagen. Blood 2000; 95:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/29\">",
"      Harris EL, Sherman SH, Georgopoulos A. Black-white differences in risk of developing retinopathy among individuals with type 2 diabetes. Diabetes Care 1999; 22:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/30\">",
"      Emanuele N, Sacks J, Klein R, et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care 2005; 28:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/31\">",
"      Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 2006; 141:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/32\">",
"      Kendall C, Wooltorton E. Rosiglitazone (Avandia) and macular edema. CMAJ 2006; 174:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/33\">",
"      Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol 2005; 123:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30422/abstract/34\">",
"      Estacio RO, McFarling E, Biggerstaff S, et al. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM. Am J Kidney Dis 1998; 31:947.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1756 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30422=[""].join("\n");
var outline_f29_45_30422=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chronic hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Autoregulation of retinal blood flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Sorbitol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Advanced glycosylation end products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Retinal microthrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Growth factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Carbonic anhydrase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ethnic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Relation to nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1756\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1756|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/55/43901\" title=\"figure 1\">",
"      Retinopathy and HbA1c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/24/7565\" title=\"figure 2\">",
"      Sorbitol pathway in diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/4/22606\" title=\"figure 3\">",
"      Glycosylation of proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/32/29197\" title=\"figure 4\">",
"      Strict glycemic control slows progression of retinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13000?source=related_link\">",
"      Aldose reductase inhibitors in the prevention of diabetic complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36023?source=related_link\">",
"      Classification and clinical features of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42501?source=related_link\">",
"      Screening for diabetic retinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_45_30423="Steroid 5-alpha-reductase 2 deficiency";
var content_f29_45_30423=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Steroid 5-alpha-reductase 2 deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30423/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30423/contributors\">",
"     James E Griffin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30423/contributors\">",
"     Jean D Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30423/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30423/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30423/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30423/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30423/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/45/30423/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroid 5-alpha-reductase 2 deficiency, a 46,XY disorder of sexual development (DSD) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/1\">",
"     1",
"    </a>",
"    ], is an autosomal recessive condition in which 46,XY subjects with bilateral testes and normal testosterone formation have impaired virilization during embryogenesis due to defective conversion of testosterone to dihydrotestosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The clinical manifestations, pathogenesis, diagnosis, and treatment of 5-alpha-reductase deficiency are reviewed here. Defects in testosterone biosynthesis and in androgen receptor function are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of disorders of the androgen receptor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17096?source=see_link\">",
"     \"Diagnosis and treatment of disorders of the androgen receptor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"     \"Uncommon causes of congenital adrenal hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110017744\">",
"    <span class=\"h2\">",
"     46,XY individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical clinical features in 46,XY males with 5-alpha-reductase 2 deficiency are those reported in the two originally recognized families [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The external genitalia usually are predominately female at birth, with the exception of clitoromegaly in some, so that most affected males are raised as females. A variable degree of virilization occurs at the time of puberty.",
"     </li>",
"     <li>",
"      The internal urogenital tract is male, consisting of epididymides, vasa deferentia, seminal vesicles, and ejaculatory ducts that empty into a blind-ending vagina. The absence of m&uuml;llerian duct derivatives indicates that anti-m&uuml;llerian hormone is produced and acts normally. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=see_link\">",
"       \"Normal sexual differentiation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pubertal gynecomastia may occur, but does not persist into adulthood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A wide spectrum of phenotypes was reported in a subsequent study of 55 patients with 5-alpha&ndash;reductase 2 deficiency including [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clitoromegaly was present in 27 (49 percent), microphallus in 18 (33 percent), and normal female external genitalia in only four (7.3 percent).",
"     </li>",
"     <li>",
"      40 patients (72 percent) were initially assigned to female gender, and of these, five (12.5 percent) switched to male sex at puberty.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Concentrations of serum testosterone and estrogens are similar to those in normal men. The level of serum luteinizing hormone (LH) is normal in about one-half of subjects and slightly elevated in the rest. Levels of serum follicle-stimulating hormone (FSH) are elevated. Because of the defect in 5-alpha-reductase 2, the ratio of serum testosterone to dihydrotestosterone is increased, basally in adults and after administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"     human chorionic gonadotropin",
"    </a>",
"    (hCG) in childhood. In the initial descriptions, affected subjects were identified because phenotypic females failed to menstruate and developed variable virilization at adolescence. Now that many affected families have been reported, it is apparent that the manifestations vary [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 55 percent of affected subjects have a blind-ending or pseudovagina in which the Wolffian ducts terminate in the upper vagina. In 40 percent the Wolffian ducts terminate in the perineum on either side of the urethra. The remainder are sufficiently virilized to be assigned male gender at birth. The testes are invariably outside the abdominal cavity either in the inguinal canals, labia majora, or scrotum, and spermatogenesis is impaired.",
"   </p>",
"   <p>",
"    One report of four individuals diagnosed as adults with intact testes found normal lumbar and hip bone mineral density in three individuals and mild lumbar osteopenia in the fourth [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/6\">",
"     6",
"    </a>",
"    ]. In another study of 16 adult subjects with the disorder, hip bone mineral density was not significantly different than a reference male population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110017677\">",
"    <span class=\"h2\">",
"     Gender-role change at puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gender role behavior can change from the female sex of rearing to male at the time of expected puberty. In a large extended kindred from the Dominican Republic, as an example, 18 of 19 subjects initially raised as females subsequently changed gender-role behavior to male at the time of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/8\">",
"     8",
"    </a>",
"    ]. In other reports, approximately 50 to 60 percent of affected individuals assigned female sex in infancy and virilizing in puberty changed their gender role behavior to male [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/9\">",
"     9",
"    </a>",
"    ]. The percentage of patients changing gender role was much lower (12.5 percent) in the report described above [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/4\">",
"     4",
"    </a>",
"    ], perhaps due to different societal responses to the condition in the different communities studied.",
"   </p>",
"   <p>",
"    The change in gender-role behavior is not unique to this disorder and has occurred in undervirilized genetic males with 17-beta-hydroxysteroid dehydrogenase 3 deficiency and other causes of impaired testosterone synthesis and in subjects with the mixed gonadal dysgenesis form of sex chromosome DSD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. However, change in gender role behavior is rare in subjects with androgen-receptor disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of disorders of the androgen receptor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A history of similarly affected family members with defective virilization is present in about 40 percent of subjects. A similar percentage are the offspring of consanguineous marriages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     46,XX individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homozygous 46,XX women with 5-alpha-reductase 2 deficiency are phenotypically normal and have normal menstruation and normal fertility, but menarche may be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nature of the enzyme abnormality in this disorder was discovered when it was demonstrated that one component of 5-alpha-reductase in cultured genital-skin fibroblasts from affected subjects was deficient [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/13\">",
"     13",
"    </a>",
"    ]. Cloning of the cDNAs that encode the enzymes revealed that there are two steroid 5-alpha-reductases, termed types 1 and 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Steroid 5-alpha-reductase type 2 is defective in subjects with the disorder, whereas the type 1 enzyme is normal [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/15\">",
"       15",
"      </a>",
"      ]. Impaired dihydrotestosterone formation in androgen target tissues impairs virilization of the male urogenital tract in embryogenesis. The low but measurable serum concentrations of dihydrotestosterone in affected subjects could be due either to residual activity of the mutant enzyme or the normal type 1 isoenzyme. Studies in families in which the type 2 enzyme is believed to be absent suggest that the dihydrotestosterone in the serum of these subjects is predominantly derived from the type 1 enzyme [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Virilization at the time of expected puberty in untreated subjects may be mediated by serum dihydrotestosterone or by testosterone itself.",
"     </li>",
"     <li>",
"      Androgen and estrogen production are in the normal male range in 5-alpha-reductase 2 deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/2\">",
"       2",
"      </a>",
"      ]. This explains the failure of affected subjects to develop permanent gynecomastia at the time of puberty. In contrast, gynecomastia at puberty is common in subjects with mutations of the androgen receptor. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder has worldwide distribution and is due to autosomal recessive loss of function mutations in the gene that encodes steroid 5-alpha-reductase type 2 (SRD5A2). Over 50 different mutations have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/5,15,16\">",
"     5,15,16",
"    </a>",
"    ]. Point mutations are responsible for most cases. Approximately 40 percent of subjects carry homozygous mutations, in keeping with the finding of frequent consanguinity in the families; the remainder are compound heterozygotes.",
"   </p>",
"   <p>",
"    Mutations are distributed throughout the coding region, and identical mutations have been detected in different ethnic groups. The R227Q mutation, which is associated with retention of approximately 3 percent of normal enzymatic activity, appears to be relatively frequent in Asian populations and may cause micropenis rather than ambiguous genitalia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/17\">",
"     17",
"    </a>",
"    ]. In some instances, recurrent mutations are the consequence of a founder effect [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of 5-alpha-reductase 2 deficiency may be suspected in infants with ambiguous genitalia or in adolescents or young adults with the characteristic phenotype and serum hormone profiles (normal male serum testosterone concentration and increased ratio of serum testosterone to dihydrotestosterone).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in testosterone biosynthesis and partial defects in androgen receptor function can cause phenotypes that are similar to those found in subjects with 5-alpha-reductase deficiency. There are, however, important clinical differences among these disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As in 5-alpha-reductase deficiency, defects in testosterone biosynthesis usually cause greater impairment in virilization of the external genitalia than of the internal urogenital tract. The most common hereditary defect in testosterone synthesis is 17-beta-hydroxysteroid dehydrogenase 3 deficiency. In this form of 46,XY DSD, serum testosterone concentrations are often in the lower normal male range, whereas serum concentrations of androstenedione, the precursor before the enzymatic block, are elevated several-fold [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Many different mutations can cause 17-beta-hydroxysteroid dehydrogenase 3 deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link&amp;anchor=H28#H28\">",
"       \"Evaluation of the infant with ambiguous genitalia\", section on 'Abnormal androgen synthesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Partial defects in androgen-receptor function can cause impaired external virilization and result in incomplete development of the male urogenital tract, including ambiguous genitalia. These disorders are usually associated with development of gynecomastia at the time of expected puberty. Normal ratios of urinary 5-beta- to 5-alpha-reduced glucocorticoid metabolites, as indicators of hepatic steroid metabolism, may be useful in excluding the diagnosis of steroid 5-alpha-reductase 2 deficiency in such children [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/22\">",
"       22",
"      </a>",
"      ]. Such ratios may also be found in subjects with 5-alpha-reductase deficiency who have had their testes removed. However, these assays are not routinely available and definitive diagnosis may require cDNA analysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=see_link\">",
"       \"Clinical manifestations and pathogenesis of disorders of the androgen receptor\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17096?source=see_link\">",
"       \"Diagnosis and treatment of disorders of the androgen receptor\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory assessment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Adolescents and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of basal concentrations of serum testosterone and dihydrotestosterone is usually sufficient for diagnosis after the expected age of puberty.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ratio of serum testosterone to dihydrotestosterone was &gt;20 in affected subjects in the extended kindred from the Dominican Republic [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/23\">",
"       23",
"      </a>",
"      ] and in another nine unrelated Brazilian families (",
"      <a class=\"graphic graphic_figure graphicRef50253 \" href=\"UTD.htm?40/15/41214\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/24\">",
"       24",
"      </a>",
"      ]. In the latter study, the ratio ranged from 35 to 84 in affected subjects as compared with 8 to 16 in normal subjects. In adults, measurement of the ratio of serum testosterone to dihydrotestosterone after administration of hCG or testosterone does not increase discrimination between affected and normal men (",
"      <a class=\"graphic graphic_figure graphicRef50253 \" href=\"UTD.htm?40/15/41214\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cultures of genital skin fibroblasts may be studied for enzyme characteristics, but these studies are costly, time-consuming, not routinely available, and may not be definitive.",
"     </li>",
"     <li>",
"      Definitive diagnosis of the mutation in the steroid 5-alpha-reductase 2 enzyme can be made by cDNA analysis using peripheral blood, biopsy material, or fibroblast cultures [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Infants and prepubertal subjects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of basal serum concentrations of testosterone and dihydrotestosterone is",
"    <strong>",
"     not",
"    </strong>",
"    sufficient for diagnosis before the expected age of puberty. In this age group, serum testosterone and dihydrotestosterone should be measured before and after multiple injections of hCG. In one report, the ratio of testosterone to dihydrotestosterone 24 hours after the last injection of hCG (administered as three daily injections of 3300 international units) was &ge;20 in affected subjects and &lt;10 in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/25\">",
"     25",
"    </a>",
"    ]. Other regimens with more prolonged hCG stimulation result in higher ratios (74 to 162 versus 3 to 26 in normal subjects) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/24\">",
"     24",
"    </a>",
"    ]. As in adults, definitive diagnosis requires cDNA analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of sex assignment in the newborn in this condition is complex because &ge;50 percent of individuals assigned the female sex undergo a change in social sex (gender role behavior) later in life. On occasion, the diagnosis is made in the newborn period. If the phenotype is male, the choice of male rearing is clear. The one situation in which male sex assignment can be made with reasonable certainty in a baby with ambiguous or female phenotype would be in individuals born into families such as the Dominican Republic family; virtually all affected members have ultimately chosen a male gender role [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because affected subjects virilize to a variable extent later in life, some experts recommend that all infants diagnosed with steroid 5-alpha-reductase 2 deficiency should be raised as males [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/26\">",
"     26",
"    </a>",
"    ]. The issue of gender assignment is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link&amp;anchor=H27#H27\">",
"     \"Management of the infant with ambiguous genitalia\", section on 'Gender assignment and surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The situation is equally complex when the diagnosis is made later in childhood in individuals raised as female. On one hand, such girls may have been aware of inappropriate gender assignment from early childhood and may be ready to make a change in social sex [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/27\">",
"     27",
"    </a>",
"    ]. On the other hand, other individuals are comfortable as females and do not wish to change social sex. The consequence is that when the diagnosis is made later in childhood or adolescence, surgical or endocrine intervention should only be done after careful psychological evaluation of the child and consultation with the parents [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/9,28,29\">",
"     9,28,29",
"    </a>",
"    ]. The age of the subject, the sex of rearing, and the choice of social sex all influence subsequent management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of the infant with ambiguous genitalia\", section on 'Psychosexual issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Subjects who maintain a female social role",
"    </span>",
"    &nbsp;&mdash;&nbsp;In light of the frequent change in gender role from female to male (see above) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/8\">",
"     8",
"    </a>",
"    ], the decision to raise an individual as female should be made only after thorough psychologic assessment to confirm the presence of female gender identity. Once the decision has been made to maintain a female social role, the management is fairly straightforward.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gonadectomy should be performed to prevent or minimize virilization and to prevent development of tumors in inguinal or labial testes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/30\">",
"       30",
"      </a>",
"      ]. Clitoromegaly may be surgically corrected by an appropriate procedure to maintain the glans clitoris. If vaginal development is insufficient, vaginal depth should be enhanced by use of dilators at the appropriate age and, if this is unsuccessful, an artificial vagina should be created surgically [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link&amp;anchor=H17#H17\">",
"       \"Management of the infant with ambiguous genitalia\", section on 'Genital surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Estrogen therapy appropriate for inducing and maintaining feminization should be started at the time of usual pubertal maturation or immediately after gonadectomy is performed in an adult. Such therapy is critical to promote breast development and to prevent osteoporosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"       \"Diagnosis and treatment of delayed puberty\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Subjects who are raised as males or change social behavior to male",
"    </span>",
"    &nbsp;&mdash;&nbsp;Raising a subject as male requires complex decisions about the time and type of surgical and hormonal therapy. Surgical correction of hypospadias and cryptorchidism (if present) should be performed by a surgeon experienced in these procedures at a time dictated by the degree of hypospadias and size of the phallus.",
"   </p>",
"   <p>",
"    Since virilization is usually less than satisfactory, even when some phallic growth occurs after the time of sexual maturation, trials of supplemental androgen are sometimes undertaken [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/24,32\">",
"     24,32",
"    </a>",
"    ]. Although pharmacologic doses of testosterone esters may raise serum dihydrotestosterone concentrations to the normal range and cause acne and growth of facial and body hair, phallic growth is minimal in adults, and the long-term safety of this treatment is not established.",
"   </p>",
"   <p>",
"    The results are different in prepubertal subjects. In one report, as an example, pharmacologic doses of testosterone (two intramuscular doses of testosterone ester 125 mg three weeks apart) led to more than a doubling of penis size [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/24\">",
"     24",
"    </a>",
"    ]. An alternate approach is to administer dihydrotestosterone itself, either in the form of a transdermal cream [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/33\">",
"     33",
"    </a>",
"    ] or an injectable ester [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/34\">",
"     34",
"    </a>",
"    ]. Both modes of dihydrotestosterone administration raise serum dihydrotestosterone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], but neither preparation is commercially available and an optimal regimen has not been established.",
"   </p>",
"   <p>",
"    Sperm counts have been very low in most patients with 5-alpha-reductase 2 deficiency in whom sperm production has been measured. Sperm counts were within the low normal range in only one individual (of nine examined) from the Dominican Republic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/35\">",
"     35",
"    </a>",
"    ]. This man was able to achieve fertility with the use of intrauterine insemination [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fertility has also been reported in men in whom 5-alpha-reductase deficiency caused isolated microphallus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/37\">",
"     37",
"    </a>",
"    ]. However, fertility in most affected men who have minimal detectable sperm production requires intrauterine insemination or in vitro fertilization with intracytoplasmic sperm injection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30423/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=see_link\">",
"     \"Intracytoplasmic sperm injection\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroid 5-alpha-reductase 2 deficiency is a rare autosomal recessive disorder in which virilization of males during development is impaired because of inadequate conversion of testosterone to its more active intracellular metabolite dihydrotestosterone.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The phenotype is striking because virilization of the external genitalia is impaired more severely than the virilization of the other parts of the male urogenital tract. As a consequence, most 46,XY males are raised as females; the mutation is silent in women who carry the same homozygous mutation.",
"     </li>",
"     <li>",
"      The clinical diagnosis is made by measuring the ratio of plasma testosterone to dihydrotestosterone in genetic males after the age of puberty, or in infants and prepubertal subjects after administration of hCG. Definitive diagnosis requires sequencing the cDNA of the gene that encodes steroid 5-alpha-reductase 2.",
"     </li>",
"     <li>",
"      Sex assignment at birth: The fact that &ge;50 to 60 percent of 46,XY patients with this disorder who are raised as females undergo change in gender role from female to male after the time of expected puberty complicates sex assignment in infants and small children. Careful psychological assessment should be performed prior to surgery to either augment male development or female development, particularly in children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The issues of sex assignment, psychosexual issues, and corrective genital surgery are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link\">",
"     \"Management of the infant with ambiguous genitalia\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/1\">",
"      Hughes IA, Houk C, Ahmed SF, et al. Consensus statement on management of intersex disorders. Arch Dis Child 2006; 91:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/2\">",
"      Walsh PC, Madden JD, Harrod MJ, et al. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974; 291:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/3\">",
"      Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/4\">",
"      Maimoun L, Philibert P, Cammas B, et al. Phenotypical, biological, and molecular heterogeneity of 5&alpha;-reductase deficiency: an extensive international experience of 55 patients. J Clin Endocrinol Metab 2011; 96:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/5\">",
"      Wilson JD, Griffin JE, Russell DW. Steroid 5 alpha-reductase 2 deficiency. Endocr Rev 1993; 14:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/6\">",
"      Frade Costa EM, Prado Arnhold IJ, Inacio M, Mendonca BB. Normal bone density in male pseudohermaphroditism due to 5alpha- reductase 2 deficiency. Rev Hosp Clin Fac Med Sao Paulo 2001; 56:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/7\">",
"      Sobel V, Schwartz B, Zhu YS, et al. Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. J Clin Endocrinol Metab 2006; 91:3017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/8\">",
"      Imperato-McGinley J, Peterson RE, Gautier T, Sturla E. Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5alpha-reductase deficiency. N Engl J Med 1979; 300:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/9\">",
"      Cohen-Kettenis PT. Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav 2005; 34:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/10\">",
"      Wilson JD. Androgens, androgen receptors, and male gender role behavior. Horm Behav 2001; 40:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/11\">",
"      Milewich L, Mendonca BB, Arnhold I, et al. Women with steroid 5 alpha-reductase 2 deficiency have normal concentrations of plasma 5 alpha-dihydroprogesterone during the luteal phase. J Clin Endocrinol Metab 1995; 80:3136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/12\">",
"      Katz MD, Cai LQ, Zhu YS, et al. The biochemical and phenotypic characterization of females homozygous for 5 alpha-reductase-2 deficiency. J Clin Endocrinol Metab 1995; 80:3160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/13\">",
"      Moore RJ, Griffin JE, Wilson JD. Diminished 5alpha-reductase activity in extracts of fibroblasts cultured from patients with familial incomplete male pseudohermaphroditism, type 2. J Biol Chem 1975; 250:7168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/14\">",
"      Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci U S A 1990; 87:3640.",
"     </a>",
"    </li>",
"    <li>",
"     Griffin JE, McPhaul MJ, Russell DW, Wilson JD. The androgen resistance syndromes: Steroid 5-alpha-reductase 2 deficiency, testicular feminization, and related disorders. In: The Metabolic and Molecular Basis of Inherited Disease, 8th, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.4117.",
"    </li>",
"    <li>",
"     The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. file://www.hgmd.cf.ac.uk/ac/index.php (Accessed on August 17, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/17\">",
"      Sasaki G, Ogata T, Ishii T, et al. Micropenis and the 5alpha-reductase-2 (SRD5A2) gene: mutation and V89L polymorphism analysis in 81 Japanese patients. J Clin Endocrinol Metab 2003; 88:3431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/18\">",
"      Mazen I, Gad YZ, Hafez M, et al. Molecular analysis of 5alpha-reductase type 2 gene in eight unrelated egyptian children with suspected 5alpha-reductase deficiency: prevalence of the G34R mutation. Clin Endocrinol (Oxf) 2003; 58:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/19\">",
"      Givens JR, Wiser WL, Summitt RL, et al. Familial male pseudohermaphroditism without gynecomastia due to deficient testicular 17-ketosteroid reductase activity. N Engl J Med 1974; 291:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/20\">",
"      Mendonca BB, Inacio M, Arnhold IJ, et al. Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 2000; 79:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/21\">",
"      Andersson S, Moghrabi N. Physiology and molecular genetics of 17 beta-hydroxysteroid dehydrogenases. Steroids 1997; 62:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/22\">",
"      Imperato-McGinley J, Peterson RE, Gautier T, et al. Hormonal evaluation of a large kindred with complete androgen insensitivity: evidence for secondary 5 alpha-reductase deficiency. J Clin Endocrinol Metab 1982; 54:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/23\">",
"      Peterson RE, Imperato-McGinley J, Gautier T, Sturla E. Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency. Am J Med 1977; 62:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/24\">",
"      Mendonca BB, Inacio M, Costa EM, et al. Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 1996; 75:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/25\">",
"      Imperato-McGinley J, Gautier T, Pichardo M, Shackleton C. The diagnosis of 5 alpha-reductase deficiency in infancy. J Clin Endocrinol Metab 1986; 63:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/26\">",
"      Chirkov GP, Bokov PIa, Druzhinina MK, Todorov IN. [Biosynthesis of ribosomal RNA in rat liver cells after inhibition of protein synthesis]. Biokhimiia 1983; 48:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/27\">",
"      Praveen EP, Desai AK, Khurana ML, et al. Gender identity of children and young adults with 5alpha-reductase deficiency. J Pediatr Endocrinol Metab 2008; 21:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/28\">",
"      Houk CP, Damiani D, Lee PA. Choice of gender in 5alpha-reductase deficiency: a moving target. J Pediatr Endocrinol Metab 2005; 18:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/29\">",
"      Sobel V, Imperato-McGinley J. Gender identity in XY intersexuality. Child Adolesc Psychiatr Clin N Am 2004; 13:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/30\">",
"      Sasaki G, Nakagawa K, Hashiguchi A, et al. Giant seminoma in a patient with 5 alpha-reductase type 2 deficiency. J Urol 2003; 169:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/31\">",
"      Costa EM, Mendonca BB, In&aacute;cio M, et al. Management of ambiguous genitalia in pseudohermaphrodites: new perspectives on vaginal dilation. Fertil Steril 1997; 67:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/32\">",
"      Price P, Wass JA, Griffin JE, et al. High dose androgen therapy in male pseudohermaphroditism due to 5 alpha-reductase deficiency and disorders of the androgen receptor. J Clin Invest 1984; 74:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/33\">",
"      Carpenter TO, Imperato-McGinley J, Boulware SD, et al. Variable expression of 5 alpha-reductase deficiency: presentation with male phenotype in a child of Greek origin. J Clin Endocrinol Metab 1990; 71:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/34\">",
"      Keenan BS, Eberle AJ, Sparrow JT, et al. Dihydrotestosterone heptanoate: synthesis, pharmacokinetics, and effects on hypothalamic-pituitary-testicular function. J Clin Endocrinol Metab 1987; 64:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/35\">",
"      Cai LQ, Fratianni CM, Gautier T, Imperato-McGinley J. Dihydrotestosterone regulation of semen in male pseudohermaphrodites with 5 alpha-reductase-2 deficiency. J Clin Endocrinol Metab 1994; 79:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/36\">",
"      Katz MD, Kligman I, Cai LQ, et al. Paternity by intrauterine insemination with sperm from a man with 5alpha-reductase-2 deficiency. N Engl J Med 1997; 336:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/37\">",
"      Nordenskj&ouml;ld A, Ivarsson SA. Molecular characterization of 5 alpha-reductase type 2 deficiency and fertility in a Swedish family. J Clin Endocrinol Metab 1998; 83:3236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30423/abstract/38\">",
"      Bourne H, Richings N, Harari O, et al. The use of intracytoplasmic sperm injection for the treatment of severe and extreme male infertility. Reprod Fertil Dev 1995; 7:237.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7470 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30423=[""].join("\n");
var outline_f29_45_30423=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110017744\">",
"      46,XY individuals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110017677\">",
"      Gender-role change at puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      46,XX individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Infants and prepubertal subjects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Subjects who maintain a female social role",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Subjects who are raised as males or change social behavior to male",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7470\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7470|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/15/41214\" title=\"figure 1\">",
"      T and DHT in 5-alpha-reductase 2 deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=related_link\">",
"      Clinical manifestations and pathogenesis of disorders of the androgen receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17096?source=related_link\">",
"      Diagnosis and treatment of disorders of the androgen receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=related_link\">",
"      Intracytoplasmic sperm injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=related_link\">",
"      Management of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=related_link\">",
"      Normal sexual differentiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=related_link\">",
"      Uncommon causes of congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_45_30424="Approach to wheezing in children";
var content_f29_45_30424=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to wheezing in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30424/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30424/contributors\">",
"     Khoulood Fakhoury, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30424/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30424/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30424/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30424/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/45/30424/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wheezing is a common presenting symptom of respiratory disease in children. A nationwide survey performed in the United States between 1988 to 1994 showed that the prevalence for wheezing amongst 2 to 3 year olds was 26 percent and amongst 9 to 11 years was 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/1\">",
"     1",
"    </a>",
"    ]. One in three children experience at least one acute wheezing illness before the age of three years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Wheezing may be either a benign, self-limited process or the presenting symptom of a significant respiratory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/4\">",
"     4",
"    </a>",
"    ]. The role of the treating clinician is to try to reach the most likely diagnosis as quickly and efficiently as possible so that therapy, if necessary, can be instituted and the parental concerns can be addressed.",
"   </p>",
"   <p>",
"    The most likely diagnosis in children with recurrent wheezing is asthma, regardless of the age of onset, evidence of atopic disease, precipitating causes, or frequency of wheezing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/5\">",
"     5",
"    </a>",
"    ]. However, other diseases can present with wheezing in childhood, and patients with asthma may not wheeze. The differential diagnosis of wheezing includes a variety of congenital and acquired conditions (",
"    <a class=\"graphic graphic_table graphicRef67370 \" href=\"UTD.htm?23/40/24204\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinical history and physical examination often allow accurate diagnosis. However, radiographic examination, pulmonary function testing, bronchoscopy, sweat chloride concentration, and selective laboratory studies are helpful tools in establishing the underlying etiology of wheezing when used appropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The initial evaluation of a wheezing child is directed toward the exclusion of alternative diagnoses, followed by a therapeutic trial of bronchodilators if asthma is suspected.",
"   </p>",
"   <p>",
"    A diagnostic approach to wheezing in childhood is presented here. An overview of recurrent wheezing phenotypes, a review of the causes of nonasthmatic wheezing in children, and the diagnosis and management of asthma are presented separately. Virus-induced wheezing and the emergent evaluation of children with acute respiratory distress are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34920?source=see_link\">",
"     \"Wheezing phenotypes and prediction of asthma in young children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=see_link\">",
"     \"Wheezing illnesses other than asthma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=see_link\">",
"     \"Virus-induced wheezing and asthma: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22216?source=see_link\">",
"     \"Treatment of recurrent virus-induced wheezing in young children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=see_link\">",
"     \"Emergent evaluation of acute respiratory compromise in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND PHYSIOLOGY OF WHEEZING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wheeze is a continuous musical sound heard during chest auscultation that lasts longer than 250 msec [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/7\">",
"     7",
"    </a>",
"    ]. It is produced by the oscillation of opposing walls of an airway narrowed almost to the point of closure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/8\">",
"     8",
"    </a>",
"    ]. It can be high-pitched or low-pitched, consist of single or multiple notes, and occur during inspiration or expiration. Wheezes can originate from airways of any size throughout the proximal conducting airways. Wheezing requires sufficient airflow to generate airway oscillation and produce sound in addition to narrowing or compression of the airway. Thus, the absence of wheezing in a patient who presents with acute asthma may be an ominous finding, suggesting impending respiratory failure.",
"   </p>",
"   <p>",
"    Wheezing caused by a large or central airway obstruction has a constant acoustical character throughout the lung, but varies in loudness depending upon the distance from the site of obstruction. It is referred to as monophonic (or homophonous) wheezing. In contrast, the degree of narrowing varies from place to place within the lung in the setting of small airway obstruction. As a result, the sounds generated also vary in quality and acoustical character and are described as polyphonic (or heterophonous) wheezes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some experts distinguish between wheezes and rhonchi based upon the dominant frequency, or pitch, of the sound. Wheezes have a dominant frequency greater than 400 Hz, whereas rhonchi are of lower frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, the clinical significance of this distinction, if any, is not well defined [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stridor refers to a monophonic wheeze that is loudest over the central airways. Stridor can be heard during inspiration, expiration, or throughout the respiratory cycle, depending on the location of obstruction. In general, inspiratory stridor is prominent in the setting of extrathoracic obstruction, whereas expiratory stridor suggests intrathoracic obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with a history of wheezing, it is crucial to ask the patient or the parents to describe what they actually are experiencing or hearing. On many occasions, the word \"wheezing\" is used as a general term to describe noisy breathing, including snoring, congestion, rattling, gurgling noises, or stridor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. It is essential to try to validate the symptom of wheezing if parental report is the only source of information and no wheezing is heard on examination of the child. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few studies that compare parent reported respiratory illness in infants with clinical diagnosis. In another study, parental report of wheezing in 139 infants and children was compared with clinical findings of wheezing and diagnosis of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/14\">",
"     14",
"    </a>",
"    ]. There was a less than 50 percent agreement between a clinician&rsquo;s finding of wheeze and asthma and parents&rsquo; report of wheeze. Fourteen percent of parents use the term wheeze to describe other noises, mainly upper airway noises.",
"   </p>",
"   <p>",
"    Two important aspects of the medical history include the patient's age at the onset of wheezing and the course of onset (acute versus gradual) (",
"    <a class=\"graphic graphic_table graphicRef67370 \" href=\"UTD.htm?23/40/24204\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70442 \" href=\"UTD.htm?4/41/4764\">",
"     table 2",
"    </a>",
"    ). Acute onset of wheezing raises the possibility of foreign body aspiration, particularly if there is a history of choking. In addition, it is helpful to distinguish between intermittent and persistent wheezing. Persistent wheezing presenting very early in life suggests a congenital or structural abnormality; in contrast, paroxysmal or intermittent wheezing is a characteristic finding in patients with asthma. Persistent wheezing with sudden onset is consistent with foreign body aspiration, whereas the slowly progressive onset of wheezing may be a sign of extraluminal bronchial compression by a growing mass or lymph node. Less frequently, patients with interstitial lung disease can present with persistent wheezing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18775?source=see_link\">",
"     \"Classification of interstitial lung disease in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link\">",
"     \"Approach to the infant and child with interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cough is a symptom commonly associated with wheezing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/15\">",
"     15",
"    </a>",
"    ]. The nature of the associated cough (wet versus dry) may be helpful in determining the underlying etiology. Wet cough typically results from excessive mucus production, mostly due to infection or inflammation (eg, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, asthma, and chronic aspiration). In contrast, pure bronchoconstriction or structural causes for airway narrowing (eg, asthma, airway malacia or compression, foreign body, vascular ring) are usually associated with a dry cough. However, the underlying etiology of a dry cough can be complicated by a secondary process, making this distinction difficult (eg, mechanical obstruction can lead to impaired mucus clearance resulting in infection and a wet cough).",
"   </p>",
"   <p>",
"    Among children younger than two years of age, the incidence of wheezing with respiratory illnesses is approximately 30 percent and peaks between two and six months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Typically, these infants present with classic coryzal symptoms that progress to coughing, wheezing, and occasionally, respiratory distress over a period of three to five days; resolution is gradual over approximately two weeks. These episodes are variably responsive to bronchodilators and systemic glucocorticoids, but not antibiotics, expectorants, or antihistamines. A symptom-free period typically ensues, followed by recurrent wheezing with subsequent viral illnesses in as many as 50 percent of babies.",
"   </p>",
"   <p>",
"    Criteria for the diagnosis of asthma and initiation of treatment are discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef61691 \" href=\"UTD.htm?40/41/41628\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51579 \" href=\"UTD.htm?14/35/14909\">",
"     table 4",
"    </a>",
"    ). Prompt institution of timely and appropriate pharmacotherapy, education, and prevention strategies are appropriate in children who meet these criteria. (See",
"    <a class=\"local\" href=\"#H1495860\">",
"     'Response to treatment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link&amp;anchor=H2#H2\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\", section on 'Indications for controller medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features in the history that favor the diagnosis of asthma include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intermittent episodes of wheezing that usually are the result of a common trigger (ie, upper respiratory infections, weather changes, exercise, or allergens)",
"     </li>",
"     <li>",
"      Seasonal variation",
"     </li>",
"     <li>",
"      Family history of asthma",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      atopy",
"     </li>",
"     <li>",
"      Good response to asthma medications",
"     </li>",
"     <li>",
"      Positive asthma predictive index (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34920?source=see_link&amp;anchor=H5515520#H5515520\">",
"       \"Wheezing phenotypes and prediction of asthma in young children\", section on 'Asthma Predictive Index'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical features that suggest a diagnosis other than asthma include the following (",
"    <a class=\"graphic graphic_table graphicRef70442 \" href=\"UTD.htm?4/41/4764\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor response to asthma medications",
"     </li>",
"     <li>",
"      A history of neonatal or perinatal respiratory problems and wheezing since birth suggests a congenital abnormality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wheezing associated with feeding or vomiting can result from gastroesophageal reflux or impaired swallowing complicated by aspiration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=see_link\">",
"       \"Sucking and swallowing disorders in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of choking, especially with associated coughing or shortness of breath, suggests foreign body aspiration, even if it does not immediately precede onset of wheezing symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"       \"Airway foreign bodies in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wheezing with little cough suggests a purely mechanical cause of obstruction, such as small airways, airway malacia, and vascular ring, since cough is a prominent component of asthma in children [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Symptoms that vary with changes in position may be caused by tracheomalacia, bronchomalacia, or vascular rings. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Poor weight gain and recurrent ear or sinus infections suggest cystic fibrosis, immunodeficiency, or ciliary dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"       \"Approach to the child with recurrent infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of progressive dyspnea, tachypnea, exercise intolerance, and failure to thrive suggest interstitial lung disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18775?source=see_link\">",
"       \"Classification of interstitial lung disease in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link\">",
"       \"Approach to the infant and child with interstitial lung disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;General examination of a wheezy child should include measurement of weight and height, vital signs including oxygen saturation, and digital inspection for the presence of cyanosis or clubbing. The latter findings suggest the presence of a wheezing illness other than asthma (",
"    <a class=\"graphic graphic_table graphicRef70442 \" href=\"UTD.htm?4/41/4764\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Chest examination should focus on the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspection for the presence of respiratory distress, tachypnea, retractions, or structural abnormalities. Pertinent findings include an increased anteroposterior (AP) diameter associated with chronic hyperinflation, pectus excavatum caused by chronic airway obstruction and exaggerated swings in intrathoracic pressure, or scoliosis complicated by airway compression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18071?source=see_link\">",
"       \"Pectus excavatum: Etiology and evaluation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33770?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Palpation to detect supratracheal lymphadenopathy or tracheal deviation.",
"     </li>",
"     <li>",
"      Percussion can define the position of the diaphragm and detect differences in resonance among lung regions, and is the most under-performed part of the examination.",
"     </li>",
"     <li>",
"      Auscultation allows identification of the characteristics and location of wheezing, as well as variations in air entry among different lung regions. A prolonged expiratory phase suggests airway narrowing. Wheezing caused by a large or central airway obstruction (eg, vascular ring, subglottic stenosis, tracheomalacia) has a constant acoustic character throughout the lung, but varies in loudness depending upon the distance from the site of obstruction. In contrast, the degree of narrowing varies from place to place within the lung in the setting of small airway obstruction (eg, asthma, cystic fibrosis, primary ciliary dyskinesia, aspiration). The presence of focal wheezing is usually indicative of a localized and mostly structural airway abnormality, and therefore airway evaluation by imaging or bronchoscopy is warranted.",
"     </li>",
"     <li>",
"      Crackles can be present in conjunction with wheezing in asthma and in a variety of other conditions, such as those leading to bronchiectasis (eg, cystic fibrosis, primary ciliary dyskinesia, immune deficiency). Early inspiratory crackles are often present in patients with asthma due to air flowing through secretions or slightly closed airways during inspiration. Late inspiratory crackles are usually associated with interstitial lung disease and early congestive heart failure. Thus, the presence of crackles does not exclude the diagnosis of asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased wheezing after bronchodilator therapy is suggestive of asthma, but does not rule comorbid conditions if clinically suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The remainder of the examination should focus on cardiac findings, including murmurs and signs of heart failure. Examination of the skin for eczema (common in atopic patients) or other cutaneous lesions may assist in diagnosis. Nasal examination may reveal signs of allergic rhinitis, sinusitis, or nasal polyps; the presence of nasal polyps in children necessitates an evaluation for cystic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H9#H9\">",
"     \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Acute bacterial rhinosinusitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest radiograph (anteroposterior [AP] and lateral films) should be considered in children with new onset wheezing of undetermined etiology or chronic persistent wheezing not responding to therapies. It is not necessary to obtain a chest radiograph with every exacerbation in children with asthma, unless there is a specific indication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute asthma exacerbations in children: Outpatient management\", section on 'Chest radiograph'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most cases, a plain chest radiograph provides a good image of the large airways, including the tracheal air column and mainstem bronchi. Plain films can also help differentiate between diffuse and focal disease. The presence of generalized hyperinflation suggests diffuse air trapping and airway disease, seen in asthma, cystic fibrosis, primary ciliary dyskinesia, and aspiration. In contrast, localized findings suggest structural abnormalities or foreign body aspiration. A chest radiograph can also detect parenchymal lung disease, atelectasis, and in some cases, areas of bronchiectasis.",
"   </p>",
"   <p>",
"    In addition, chest radiographs may reveal cardiomegaly, enlarged pulmonary vessels, pulmonary edema, or other signs of cardiac failure. Plain radiographs also are helpful in detecting mediastinal masses or enlarged lymph nodes, and may suggest the presence of vascular rings (eg, right aortic arch). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link\">",
"     \"Vascular rings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other radiologic studies may be helpful in selected cases (",
"    <a class=\"graphic graphic_table graphicRef62889 \" href=\"UTD.htm?16/11/16573\">",
"     table 5",
"    </a>",
"    ). Chest computed tomography can provide detailed anatomy of the mediastinum, large airways, and lung parenchyma. Magnetic resonance imaging with contrast (magnetic resonance angiography, MRA) or multidetector computed tomography (MDCT)",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/20\">",
"     20",
"    </a>",
"    ] should be considered when a vascular problem is suspected.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    swallow may help in identifying vascular rings, swallowing dysfunction, aspiration syndromes including gastroesophageal reflux, and some cases of tracheoesophageal fistula; however, this study is indicated only when these conditions are suspected (",
"    <a class=\"graphic graphic_table graphicRef62889 \" href=\"UTD.htm?16/11/16573\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=see_link&amp;anchor=H367105399#H367105399\">",
"     \"Aspiration due to swallowing dysfunction in infants and children\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=see_link\">",
"     \"Gastroesophageal reflux in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PULMONARY FUNCTION TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function tests (PFTs) are an important component of the diagnostic evaluation of a wheezy child. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"     \"Overview of pulmonary function testing in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infant pulmonary function testing, if available, is helpful in assessing airway obstruction. Moreover, this test can be used to quantify the response to bronchodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/5,21,22\">",
"     5,21,22",
"    </a>",
"    ]. Airway resistance and functional residual capacity also can be measured using gas dilution or body plethysmography, and can help quantify airway obstruction and the response to bronchodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In older children who are cooperative, pulmonary function testing with inspiratory and expiratory flow-volume loops is helpful in determining the presence, degree, and location of airway obstruction, as well as the response to bronchodilators (",
"    <a class=\"graphic graphic_figure graphicRef63544 \" href=\"UTD.htm?40/55/41853\">",
"     figure 1",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     Methacholine",
"    </a>",
"    challenge testing and exercise testing can confirm airway hyperreactivity in patients for whom the diagnosis of asthma still is in question. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"     \"Overview of pulmonary function testing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1495860\">",
"    <span class=\"h1\">",
"     RESPONSE TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with diffuse wheezing, a trial of inhaled bronchodilators can be used to confirm the presence of reversible airway disease. However, a partial or negative response may not rule out asthma. Inflammation and airway swelling may contribute to wheezing, in addition to bronchoconstriction, especially in infants and young children. Thus, if asthma is still suspected in a patient with chronic or persistent symptoms, the combination of inhaled glucocorticoids and bronchodilators for at least two weeks (or five to seven days of oral glucocorticoids if the patient has more severe symptoms) may result in significant improvement in symptoms and help in making the diagnosis of asthma. . Further workup is indicated if the response to this therapy is inadequate or if a comorbid condition is still suspected in a patient who had a positive response to bronchodilator. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few laboratory investigations that are useful in the initial evaluation of the wheezy child. In most cases, the probable diagnosis is suspected on the basis of the clinical history and physical examination. The role of laboratory tests, when indicated, is either to confirm the diagnosis or to rule out other less likely diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/6\">",
"     6",
"    </a>",
"    ]. Complete blood counts are important in patients with chronic or systemic symptoms and may reveal anemia, leukocytosis, or leukopenia. Eosinophilia in this setting supports an underlying allergic process or possible parasitic infection. Further studies should be obtained based upon the suspected diagnosis (",
"    <a class=\"graphic graphic_table graphicRef62889 \" href=\"UTD.htm?16/11/16573\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Testing for infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infection is an important cause of wheezing in children and is mediated through numerous mechanisms. The interrelationship of viral infection, wheezing, and the development of asthma in children is complex and changes according to the patient's age, the presence of atopy, and environmental factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=see_link\">",
"     \"Virus-induced wheezing and asthma: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Viruses in the Paramyxoviridae family (eg, respiratory syncytial virus and parainfluenza virus) and picornavirus family (eg, human rhinovirus) are important precipitants of wheezing in young children. Metapneumovirus, another member of the Paramyxoviridae family, is a newly recognized human pathogen that can result in upper and lower respiratory tract infection and may present with wheezing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Thus, viral studies can be helpful in confirming the etiology of wheezing in young children presenting with symptoms suggestive of bronchiolitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=see_link\">",
"     \"Human metapneumovirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=see_link\">",
"     \"Virus-induced wheezing and asthma: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link&amp;anchor=H11#H11\">",
"     \"Parainfluenza viruses in children\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link&amp;anchor=H25#H25\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sputum stain and cultures may be useful in a setting suggestive of bacterial infections, including atypical infections (eg, mycobacterial or fungal infections), that can result in wheezing. PPD skin testing and specific serologic assays can be helpful if these infections are suspected. Serologic testing for Mycoplasma may be considered if such an infection is suspected, since Mycoplasma is an increasingly recognized cause of wheezing and may predispose children to the subsequent development of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H7#H7\">",
"     \"Mycoplasma pneumoniae infection in children\", section on 'Possible relation to asthma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=see_link&amp;anchor=H6#H6\">",
"     \"Tuberculosis disease in children\", section on 'Pulmonary tuberculosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sweat chloride test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sweat chloride test allows clinicians to assess physiologic changes associated with cystic fibrosis and is indicated in children with chronic lung problems, including wheezing. It is expected that the majority of patient with cystic fibrosis will be diagnosed at birth due to newborn screening for cystic fibrosis. However, false negatives can occur. Thus, obtaining sweat test is appropriate if clinical suspicion of the disease remains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of diarrhea, failure to thrive,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clubbing should raise the suspicion for cystic fibrosis and warrants further evaluation. One should also have a low threshold to obtain this test in a patient with persistent or recurrent pulmonary symptoms that are unresponsive to asthma therapies, especially when wheezing is associated with a chronic productive cough, since identifying a patient with cystic fibrosis has major implications for the patient, the family, and future reproductive decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/18\">",
"     18",
"    </a>",
"    ]. The sweat chloride test should be undertaken at a facility with substantial experience, and clinicians interpreting the results should be aware of other conditions that result in elevated sweat chloride concentrations (",
"    <a class=\"graphic graphic_table graphicRef78885 \" href=\"UTD.htm?25/39/26235\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1495511\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin levels can be used to screen for immunodeficiencies. Elevated IgE can be indicative of an allergic process. If there is a high suspicion of immunodeficiency, then a more detailed immunological workup is appropriate (",
"    <a class=\"graphic graphic_table graphicRef62889 \" href=\"UTD.htm?16/11/16573\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy should be considered in patients with suspected foreign body aspiration, persistent symptoms, or inadequate response to therapy. Flexible bronchoscopy performed under conscious sedation is used to evaluate the airways during spontaneous breathing and to exclude tracheomalacia. Nasopharyngoscopy, which allows visualization of the vocal cords and larynx without lower airway endoscopy, is a less invasive alternative in infants and children with evidence of extrathoracic obstruction. This approach provided a diagnosis in 75 of 82 cases (91 percent) in one series, without evidence of lower airway disease during a mean follow-up interval of six years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30424/abstract/27\">",
"     27",
"    </a>",
"    ]. Bronchoscopy with bronchoalveolar lavage should be obtained if infection, aspiration, or interstitial lung disease are suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link\">",
"     \"Approach to the infant and child with interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=see_link&amp;anchor=H367105399#H367105399\">",
"     \"Aspiration due to swallowing dysfunction in infants and children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wheezing is a common presenting symptom of respiratory disease in children. It may be either a benign, self-limited process or the presenting symptom of a significant respiratory disease. The most likely diagnosis in children with recurrent wheezing is asthma. However, other diseases can present with wheezing in childhood, and patients with asthma may not wheeze (",
"      <a class=\"graphic graphic_table graphicRef67370 \" href=\"UTD.htm?23/40/24204\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A wheeze is a continuous musical sound heard during chest auscultation that lasts longer than 250 msec. It is produced by the oscillation of opposing walls of an airway narrowed almost to the point of closure. It can be high-pitched or low-pitched, consist of single or multiple notes, occur during inspiration or expiration, and originate from airways of any size. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and physiology of wheezing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a patient presents with a history of wheezing, it is crucial to ask the patient or the parents to describe what they actually are experiencing or hearing. On many occasions, the word \"wheezing\" is used as a general term to describe noisy breathing, including snoring, congestion, gurgling noises, or stridor. Two important aspects of the medical history include the patient's age at the onset of wheezing and the course of onset (acute versus gradual). Certain clinical features favor the diagnosis of asthma or suggest another diagnosis (",
"      <a class=\"graphic graphic_table graphicRef70442 \" href=\"UTD.htm?4/41/4764\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General examination of a wheezy child should include measurement of weight and height, vital signs including oxygen saturation, digital inspection for the presence of cyanosis or clubbing, a complete chest examination, and cardiac, skin, and nasal examinations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anteroposterior (AP) and lateral chest radiographs are suggested in children with new onset wheezing of undetermined etiology or chronic persistent wheezing not responding to therapies. Other radiologic studies may be helpful in selected cases (",
"      <a class=\"graphic graphic_table graphicRef62889 \" href=\"UTD.htm?16/11/16573\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary function tests (PFTs) are an important component of the diagnostic evaluation of a wheezy child. Infant pulmonary function testing, if available, is helpful in assessing airway obstruction. In older children who are cooperative, pulmonary function testing with inspiratory and expiratory flow-volume loops is helpful in determining the presence, degree, and location of airway obstruction, as well as the response to bronchodilators (",
"      <a class=\"graphic graphic_figure graphicRef63544 \" href=\"UTD.htm?40/55/41853\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pulmonary function tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients suspected of having asthma, a trial of inhaled bronchodilators with or without glucocorticoids can be used to confirm the diagnosis prior to initiating a more extensive workup. Further workup is indicated if the response to therapy is inadequate. (See",
"      <a class=\"local\" href=\"#H1495860\">",
"       'Response to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are few laboratory investigations that are useful in the initial evaluation of the wheezy child. Any studies obtained beyond chest radiographs and PFTs should be based upon the suspected diagnosis (",
"      <a class=\"graphic graphic_table graphicRef62889 \" href=\"UTD.htm?16/11/16573\">",
"       table 5",
"      </a>",
"      ). These studies include tests to examine for viral, bacterial, or fungal infections; sweat chloride test to diagnose cystic fibrosis, evaluation for immunodeficiency or allergy; and endoscopy to examine for foreign body aspiration, tracheomalacia, or interstitial lung disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Laboratory studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/1\">",
"      Eldeirawi K, Persky VW. History of ear infections and prevalence of asthma in a national sample of children aged 2 to 11 years: the Third National Health and Nutrition Examination Survey, 1988 to 1994. Chest 2004; 125:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/2\">",
"      Taussig LM, Wright AL, Holberg CJ, et al. Tucson Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol 2003; 111:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/3\">",
"      Bloomberg GR. Recurrent wheezing illness in preschool-aged children: assessment and management in primary care practice. Postgrad Med 2009; 121:48.",
"     </a>",
"    </li>",
"    <li>",
"     Dorkin HL. Noisy breathing. In: Respiratory disease in children: Diagnosis and management, Loughlin GM, Eigen H (Eds), Williams and Wilkins, 1994. p.167.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/5\">",
"      Martinati LC, Boner AL. Clinical diagnosis of wheezing in early childhood. Allergy 1995; 50:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/6\">",
"      Chipps BE. Evaluation of infants and children with refractory lower respiratory tract symptoms. Ann Allergy Asthma Immunol 2010; 104:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/7\">",
"      Loudon R, Murphy RL Jr. Lung sounds. Am Rev Respir Dis 1984; 130:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/8\">",
"      Forgacs P. The functional basis of pulmonary sounds. Chest 1978; 73:399.",
"     </a>",
"    </li>",
"    <li>",
"     Panitch HB. Wheezing and lower airway obstruction. In: A practical guide to pediatric respiratory disease, Schidlow D, Smith D (Eds), Mosby, St. Louis 1994. p.39.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/10\">",
"      Meslier N, Charbonneau G, Racineux JL. Wheezes. Eur Respir J 1995; 8:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/11\">",
"      Mikami R, Murao M, Cugell DW, et al. International Symposium on Lung Sounds. Synopsis of proceedings. Chest 1987; 92:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/12\">",
"      Finder JD. Understanding airway disease in infants. Curr Probl Pediatr 1999; 29:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/13\">",
"      Mellis C. Respiratory noises: how useful are they clinically? Pediatr Clin North Am 2009; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/14\">",
"      Cane RS, Ranganathan SC, McKenzie SA. What do parents of wheezy children understand by \"wheeze\"? Arch Dis Child 2000; 82:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/15\">",
"      Goldsobel AB, Chipps BE. Cough in the pediatric population. J Pediatr 2010; 156:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/16\">",
"      Wright AL, Holberg CJ, Martinez FD, et al. Breast feeding and lower respiratory tract illness in the first year of life. Group Health Medical Associates. BMJ 1989; 299:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/17\">",
"      Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/18\">",
"      Fireman P. The wheezing infant. Pediatr Rev 1986; 7:247.",
"     </a>",
"    </li>",
"    <li>",
"     Tinker E, Charles MD. Not all that wheezes is asthma. In: Emergency medicine news, 2001. Vol 23, Issue 8, p.36,57.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/20\">",
"      McLaren CA, Elliott MJ, Roebuck DJ. Vascular compression of the airway in children. Paediatr Respir Rev 2008; 9:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/21\">",
"      Morgan WJ, Geller DE, Tepper RS, Taussig LM. Partial expiratory flow-volume curves in infants and young children. Pediatr Pulmonol 1988; 5:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/22\">",
"      Hilman BC. Evaluation of the wheezing infant. Allergy Proc 1994; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/23\">",
"      Jartti T, van den Hoogen B, Garofalo RP, et al. Metapneumovirus and acute wheezing in children. Lancet 2002; 360:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/24\">",
"      Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004; 350:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/25\">",
"      Biscardi S, Lorrot M, Marc E, et al. Mycoplasma pneumoniae and asthma in children. Clin Infect Dis 2004; 38:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/26\">",
"      Principi N, Esposito S. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections. Lancet Infect Dis 2001; 1:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30424/abstract/27\">",
"      O'Sullivan BP, Finger L, Zwerdling RG. Use of nasopharyngoscopy in the evaluation of children with noisy breathing. Chest 2004; 125:1265.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5752 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30424=[""].join("\n");
var outline_f29_45_30424=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND PHYSIOLOGY OF WHEEZING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PULMONARY FUNCTION TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1495860\">",
"      RESPONSE TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Testing for infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sweat chloride test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1495511\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5752\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5752|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/55/41853\" title=\"figure 1\">",
"      Flow volume loop airway lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5752|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/40/24204\" title=\"table 1\">",
"      Causes of wheeze in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/41/4764\" title=\"table 2\">",
"      Nonasthmatic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/41/41628\" title=\"table 3\">",
"      Asthma severity 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/35/14909\" title=\"table 4\">",
"      Asthma severity 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/11/16573\" title=\"table 5\">",
"      Diagnostic eval wheezing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/39/26235\" title=\"table 6\">",
"      Causes elevated sweat chloride",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=related_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=related_link\">",
"      Approach to the infant and child with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=related_link\">",
"      Aspiration due to swallowing dysfunction in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=related_link\">",
"      Assessment of stridor in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18775?source=related_link\">",
"      Classification of interstitial lung disease in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33770?source=related_link\">",
"      Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=related_link\">",
"      Emergent evaluation of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=related_link\">",
"      Gastroesophageal reflux in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=related_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18071?source=related_link\">",
"      Pectus excavatum: Etiology and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=related_link\">",
"      Sucking and swallowing disorders in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22216?source=related_link\">",
"      Treatment of recurrent virus-induced wheezing in young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=related_link\">",
"      Virus-induced wheezing and asthma: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=related_link\">",
"      Wheezing illnesses other than asthma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34920?source=related_link\">",
"      Wheezing phenotypes and prediction of asthma in young children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_45_30425="Overview of the management of acute kidney injury (acute renal failure)";
var content_f29_45_30425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of acute kidney injury (acute renal failure)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30425/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30425/contributors\">",
"     Mark D Okusa, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30425/contributors\">",
"     Mitchell H Rosner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30425/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30425/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30425/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/45/30425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6569973\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute renal failure (ARF) is an abrupt and usually reversible decline in the glomerular filtration rate (GFR). This results in an elevation of serum blood urea nitrogen (BUN), creatinine, and other metabolic waste products that are normally excreted by the kidney.",
"   </p>",
"   <p>",
"    The term acute kidney injury (AKI) rather than ARF is increasingly used by the nephrology community to refer to the acute loss of kidney function. This term also highlights that injury to kidney that does not results in &ldquo;failure&rdquo; is also of great clinical significance. In this topic review, the acute loss of kidney function will be referred to as AKI.",
"   </p>",
"   <p>",
"    The initial assessment of patients with AKI and management of the major complications of AKI are discussed here. The incidence, causes, diagnosis, and prevention of AKI are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=see_link\">",
"     \"Renal and patient outcomes after acute tubular necrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=see_link\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2271117744\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKI has multiple possible etiologies. Among hospitalized patients, AKI is most commonly due to acute tubular necrosis (ATN) from ischemia, nephrotoxin exposure or sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/1\">",
"     1",
"    </a>",
"    ]. The pathogenesis of ATN is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other frequent causes of AKI, among either ambulatory or hospitalized patients, include volume depletion, urinary obstruction, rapidly progressive glomerulonephritis, and acute interstitial nephritis. The pathogeneses of these disorders are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=see_link\">",
"     \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6569987\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) is generally detected by an increase in the serum creatinine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a decrease in urine output. The magnitude of the increase in creatinine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decrease in urine output that is required to establish a diagnosis of AKI has been the focus of multiple expert consensus groups. The purpose of establishing a precise definition of AKI is in order to allow better interpretation of epidemiologic and clinical studies and to identify potential therapies. The potential limitations of the different consensus criteria that have been proposed are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link\">",
"     \"Definition of acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using the KDIGO criteria, AKI is defined as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An increase in serum creatinine of &ge;0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&ge;26.5",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      within 48 hours;",
"     </li>",
"     <li>",
"      An increase in serum creation of &ge;1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or",
"     </li>",
"     <li>",
"      Urine volume &lt;0.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for more than 6 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The KDIGO criteria stage the severity of AKI as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 1 AKI &mdash; 1.5 to 1.9 times baseline OR &ge;0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&ge;26.5",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      increase in the serum creatinine, OR urine output &lt;0.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for 6 to 12 hours.",
"     </li>",
"     <li>",
"      Stage 2 AKI &mdash; 2.0 to 2.9 times baseline increase in the serum creatinine OR urine output &lt;0.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for &ge;12 hours.",
"     </li>",
"     <li>",
"      Stage 3 AKI &mdash; 3.0 times baseline increase in the serum creatinine OR increase in serum creatinine to &ge;4.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&ge;353.6",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      OR urine output of &lt;0.3",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for &ge;24 hours, OR anuria for &ge;12 hours OR the initiation of renal replacement therapy OR, in patients &lt;18 years, decrease in estimated GFR to &lt;35",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m",
"      <sup>",
"       2",
"      </sup>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2271118042\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION AFTER DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among many patients, acute kidney injury (AKI) is mild and is manifested only by a transient increase in the serum creatinine or fall in urine output. However, AKI can cause life-threatening complications, even among those with relatively less-severe disease. In addition, the serum creatinine will not accurately reflect the GFR in patients who are not in steady state. Thus, among patients who have just developed AKI and in whom the serum creatinine is actively increasing, the estimated GFR based upon the serum creatinine will overestimate the actual GFR. Conversely, among patients who are recovering from AKI, the estimated GFR may underestimate the actual GFR.",
"   </p>",
"   <p>",
"    All patients who present with AKI must be carefully evaluated both for reversible causes such as hypotension, volume depletion or obstruction, and for the presence of complications such as hyperkalemia and volume overload. (See",
"    <a class=\"local\" href=\"#H6569994\">",
"     'Management'",
"    </a>",
"    below.) The initial evaluation of the patient with AKI is directed at determining the cause and identifying the complications that may require immediate attention.",
"   </p>",
"   <p>",
"    The diagnostic evaluation to determine the cause of AKI is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\", section on 'Evaluation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major complications of AKI include volume overload, hyperkalemia, metabolic acidosis, hypocalcemia, and hyperphosphatemia. With severe forms, mental status changes may be present. Hyperuricemia and hypermagnesemia may also occur. The initial assessment therefore should include the careful evaluation of volume status and measurement of serum electrolytes, particularly potassium and bicarbonate, and serum phosphate, calcium, and albumin. We also check serum uric acid, magnesium and a complete blood count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6569994\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6570002\">",
"    <span class=\"h2\">",
"     Immediate therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of life-threatening fluid and electrolyte abnormalities due to AKI should be started immediately. Common complications of AKI include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fluid overload",
"     </li>",
"     <li>",
"      Hyperkalemia (serum potassium &gt;5.5",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      or a rapidly increasing serum potassium",
"     </li>",
"     <li>",
"      Signs of uremia, such as pericarditis, or an otherwise unexplained decline in mental status",
"     </li>",
"     <li>",
"      Severe metabolic acidosis (pH less than 7.1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with any of these complications despite appropriate medical therapy generally require urgent dialysis. However, since hemodialysis often cannot be immediately provided, such patients usually require medical treatment during the period prior to the initiation of hemodialysis. Appropriate measures are discussed in sections below or in other topic reviews to which links are provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6570009\">",
"    <span class=\"h2\">",
"     Volume issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment of volume status is performed in all patients who present with AKI since correction of volume depletion or volume overload (especially when associated with worsening cardiac output) may reverse or ameliorate AKI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35223?source=see_link\">",
"     \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44456?source=see_link\">",
"     \"Cardiorenal syndrome: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6570016\">",
"    <span class=\"h3\">",
"     Volume depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless contraindicated, the patient with a clinical history consistent with fluid loss (such as vomiting and diarrhea), a physical examination consistent with hypovolemia (hypotension and tachycardia),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oliguria should be administered intravenous fluid therapy. This fluid challenge attempts to identify prerenal failure that can progress to AKI if not treated promptly. Studies have shown that prompt reversal of volume depletion may prevent or limit kidney injury due to acute tubular necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link\">",
"     \"Crush-related acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .) However, such fluid infusion is contraindicated in those with obvious volume overload or heart failure.",
"   </p>",
"   <p>",
"    Fluids may be either crystalloid or colloid. Crystalloid solutions, such as isotonic saline are preferred for initial therapy since studies have shown that colloid solutions provide no additional benefit and are more expensive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Colloid versus crystalloid'",
"    </a>",
"    .) Potassium-containing crystalloid solutions, such as lactated Ringers solution, should be avoided since the kidney may not be able to excrete potassium and hyperkalemia may result. There continues to be much debate as to which intravenous fluid should be administered since large volumes of normal saline may result in hyperchloremic metabolic acidosis and a more pH-balanced solution may be of greater benefit.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H10406742#H10406742\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Chloride-restrictive fluids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluids should be targeted to physiologic endpoints such as mean arterial pressure or urine output, or, among patients who in whom invasive monitoring is utilized, to dynamic changes in cardiac output. The optimal infusion rate varies depending on the clinical status and comorbidities of the patient. Overly aggressive volume repletion should be avoided as excessive volume expansion may lead to pulmonary congestion, especially in septic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/3\">",
"     3",
"    </a>",
"    ]. We suggest judicious administration beginning with one to three liters of fluid with careful and repeated clinical assessment to assess the patient's response to this therapy. In some cases additional fluid therapy may be necessary (severe burns, acute pancreatitis).",
"   </p>",
"   <p>",
"    The total amount of administered volume depends upon the degree of volume depletion on presentation and on ongoing losses. The restoration of adequate urine flow and improvement in renal function with fluid resuscitation is consistent with a diagnosis of prerenal disease. Patients who do not respond to administered volume with an increase in urine output or decrease in the serum creatinine are unlikely to have prerenal disease and more likely to have established ATN or other forms of intrinsic AKI such as acute or rapidly progressive glomerulonephritis or acute interstitial nephritis. However volume status may be difficult to assess among some patients and prerenal disease may not be reliably excluded after the initial administration of fluid: among selected patients in whom urine output is not restored with administered volume, invasive monitoring may be required to adequately assess the patient's fluid status and help guide further therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with relatively mild volume depletion may not have an obvious history of volume loss. In addition, less severe volume depletion is difficult to accurately detect on clinical examination especially in elderly patients. In this setting, AKI may still be reversed, at least in part, by fluid administration. Thus, in the absence of overt volume depletion, we frequently administer intravenous saline at a variable rate based upon clinical status. Although no consensus exists to guide therapy, among hemodynamically stable patients who do not have overt evidence of volume depletion, we administer 75 to 100 mL per hour. If this approach is undertaken, the patient's clinical status must be closely monitored to ensure that volume overload does not occur and that the rate of administration is sufficient to keep up with ongoing fluid losses. Once again, fluid therapy should be targeted to physiological endpoints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6570023\">",
"    <span class=\"h3\">",
"     Volume overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypervolemia may be present upon initial evaluation or occur due to excessive fluid administration in the setting of impaired ability to excrete sodium and water. This is especially true for patients with sepsis who commonly receive aggressive intravenous fluid resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Intravenous fluids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Daily fluid balance is commonly positive in critically ill patients with ATN as a result of obligate fluid intake due to the administration of antibiotics, other intravenous medications, and nutritional support. This may result in progressive volume expansion and pulmonary edema, which may be especially poorly tolerated in patients with acute lung injury.",
"   </p>",
"   <p>",
"    Less commonly, volume overload may result from primary left ventricular dysfunction and cause AKI, or type I cardiorenal syndrome. The diagnosis and treatment of cardiorenal syndrome are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35223?source=see_link\">",
"     \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44456?source=see_link\">",
"     \"Cardiorenal syndrome: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diuretics may be used to relieve hypervolemia among patients with AKI. In a post hoc analysis of data from a multicenter randomized trial that compared liberal versus conservative fluid management among patients with acute lung injury, a positive fluid balance was associated with mortality among 306 patients who developed AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/4\">",
"     4",
"    </a>",
"    ]. A higher",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    dose was associated with decreased mortality but this effect was not significant after adjusting for fluid balance. The full results of this trial are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link&amp;anchor=H15#H15\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\", section on 'Fluid management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, we generally do not use diuretics for prolonged therapy to postpone the initiation of dialysis, since dialysis offers the most efficient method of volume removal in patients with AKI from any cause, and allows clinicians to optimize nutritional support and the use of intravenous medications. However, although several observational studies have demonstrated an association between the severity of volume overload at the time of initiation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], there are no studies that have demonstrated a benefit of early initiation of dialysis for volume management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .) If diuretics are used to treat volume overload, then the patient should be regularly assessed to see if urine output responds. If there is no increase in urine output then alternative therapies such as dialysis should be initiated.",
"   </p>",
"   <p>",
"    If diuretics are used as temporizing agents to relieve volume overload, loop diuretics are the preferred agents as they provide a greater natriuretic effect than thiazide diuretics. In patients who are refractory to high doses of loop diuretics, concomitant administration of a thiazide diuretic may achieve effective diuresis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/40/650?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of refractory edema in adults\", section on 'Thiazide plus loop diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among hospitalized patients, diuretics are generally given intravenously rather than orally since the absorption of oral agents is variable in patients with decreased intestinal perfusion and motility and in those with mucosal edema. The optimal diuretic dose and regimen is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/40/650?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of refractory edema in adults\", section on 'Basic principles of diuretic dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6570030\">",
"    <span class=\"h2\">",
"     Hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia is a common and potentially life-threatening complication of AKI. It is especially prevalent in oliguric patients who are catabolic or have evidence of active cellular break-down, such as rhabdomyolysis and tumor lysis syndrome.",
"   </p>",
"   <p>",
"    There are very few symptoms or signs of hyperkalemia, and these tend to occur only with very high serum potassium levels and are related to impaired neuromuscular transmission and cardiac conduction abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=see_link\">",
"     \"Clinical manifestations of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, all patients with AKI and hyperkalemia that is refractory to medical therapy should be dialyzed unless hyperkalemia is mild (ie, &lt;5.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and the cause of AKI is known to be easily reversed (such as prerenal AKI due to volume depletion or ACE inhibitors).",
"   </p>",
"   <p>",
"    Among patients who require dialysis, medical therapy of hyperkalemia is often required while dialysis is being arranged. Immediate therapy is warranted if electrocardiographic changes or peripheral neuromuscular abnormalities are present, regardless of the degree of hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific treatment of hyperkalemia is directed at antagonizing the membrane effects of potassium, driving extracellular potassium into the cells, or removing excess potassium from the body.",
"   </p>",
"   <p>",
"    The indications for specific medical therapies are discussed at length elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not dialyze, at least initially, patients with mild hyperkalemia and AKI that is from a known reversible cause (such as volume depletion or an ACE",
"    <span class=\"nowrap\">",
"     inhibitor/ARB).",
"    </span>",
"    We treat such patients with a low potassium diet, and volume administration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    discontinuation of the ACE inhibitor or ARB. Such patients should be followed closely to make certain that such conservative therapy is effective.",
"   </p>",
"   <p>",
"    We also do not dialyze, at least initially, patients who have AKI from a cause that is not readily reversible, such as ATN, and who have hyperkalemia that is adequately treated with medical therapy. However, depending upon other variables (such as the time of day and available medical staff), preparations for dialysis, such as placement of a dialysis catheter, may be considered for such patients, since hyperkalemia is likely to recur unless renal function recovers. This is especially true among patients who are oliguric or anuric, but the approach must be individualized for each patient.",
"   </p>",
"   <p>",
"    In all patients with AKI, potassium in infusions and medications should be avoided as much as possible. Dietary potassium intake should be restricted to approximately 2 grams daily. Patients who have severe hyperkalemia (defined as K greater than 6.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    or rapidly rising serum potassium, should not receive any dietary potassium until hyperkalemia can be addressed (either by dialysis or medical therapy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6570037\">",
"    <span class=\"h2\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The excretion of acid and regeneration of bicarbonate is impaired in the setting of a low GFR resulting in metabolic acidosis. Much of the acid that is normally excreted by the kidney is the product of daily metabolism. However, other factors usually contribute to severe acidosis among patients with AKI who are often critically ill. For example, patients with AKI due to sepsis, trauma, and multi-organ failure often have increased production of lactic acid or ketoacids. Other patients who present with AKI may have metabolic acidosis resulting from loss of bicarbonate from diarrhea or, less commonly, renal tubular acidosis.",
"   </p>",
"   <p>",
"    Commonly used treatment for metabolic acidosis include dialysis and bicarbonate administration. Among patients with AKI, the choice of therapy depends upon the absence or presence of volume overload and the underlying cause and severity of the acidosis.",
"   </p>",
"   <p>",
"    We dialyze patients with severe oligo-anuric AKI who are volume overloaded and have severe metabolic acidosis (a pH&lt;7.1), regardless of the cause of acidosis. Physiologic studies have suggested that this degree of acidemia may produce hemodynamic instability related to reduced left ventricular contractility, arrhythmias, arterial vasodilation and venoconstriction and impaired responsiveness to catecholamine vasopressors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/8-15\">",
"     8-15",
"    </a>",
"    ]. Dialysis is preferred to the administration of bicarbonate among patients who are volume overloaded because bicarbonate administration results in a large sodium load that may cause or contribute to volume overload. Even among patients who are not volume overloaded on exam, bicarbonate may cause volume overload among patients who are oliguric or anuric, and should be used cautiously.",
"   </p>",
"   <p>",
"    In general, we also dialyze patients with AKI and organic acidosis (ie, lactic or ketoacidosis) and pH less than 7.10 even if they are not volume overloaded and especially if they are oliguric or anuric since such patients are at risk for becoming volume overloaded with bicarbonate therapy.",
"   </p>",
"   <p>",
"    However, among patients with AKI who are not volume overloaded and have no other indication for acute dialysis, bicarbonate may be administered instead of dialysis in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-anion gap acidosis related to diarrhea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link&amp;anchor=H15#H15\">",
"       \"Approach to the adult with metabolic acidosis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe organic acidosis (pH&lt;7.1",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      while awaiting dialysis or in patients in whom the cause of AKI is readily reversible (such as prerenal AKI due to volume depletion or obstruction).",
"     </li>",
"     <li>",
"      Intravenous bicarbonate may also be indicated among patients with AKI due to rhabdomyolysis in order to prevent further renal injury (ie, ATN) providing other indications for dialysis are not present and the patient is not volume overloaded. This possible indication for bicarbonate is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link\">",
"       \"Crush-related acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A reasonable goal for patients with metabolic acidosis due to bicarbonate loss from diarrhea who are treated with bicarbonate is a serum bicarbonate between 20 and 22",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and pH greater than 7.20 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/16\">",
"     16",
"    </a>",
"    ]. Among such patients, the total amount of bicarbonate that will be needed can be estimated from the calculated bicarbonate deficit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the adult with metabolic acidosis\", section on 'Calculation of bicarbonate deficit'",
"    </a>",
"    .) The rate of bicarbonate administration is dependent upon severity of acidosis and upon the volume status of the patient.",
"   </p>",
"   <p>",
"    We do not dialyze patients with mild organic acidosis (ie, pH&ge;7.1) unless they have another indication. The treatment of such patients is primarily directed at reversing the underlying causes of excessive acid production. This includes the treatment of sepsis and the optimization of ventilation and blood perfusion to minimize lactic acid production, and the administration of insulin to patients who have diabetic ketoacidosis. Exogenous sources of acids (such as salicylates) should be removed. The use of bicarbonate is controversial among such patients. We do not give bicarbonate to patients with mild organic acidosis, as there are no data that suggest benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link&amp;anchor=H12631281#H12631281\">",
"     \"Bicarbonate therapy in lactic acidosis\", section on 'Which patients should receive bicarbonate therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two randomized trials failed to find a benefit of bicarbonate therapy in critically ill patients with lactic acidosis and pH values greater than 7.1:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a crossover study, 14 patients with lactic acidosis (serum bicarbonate less than 17",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      and arterial lactate greater than 2.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in a single intensive care unit received, in random order, 2",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      and an equivalent dose of sodium chloride [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/18\">",
"       18",
"      </a>",
"      ]. Bicarbonate therapy produced a significant rise in arterial pH (from 7.22 to 7.36) and serum bicarbonate (from 12 to 18",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      However, the hemodynamic responses to sodium bicarbonate and sodium chloride, including cardiac output, mean arterial pressure, and pulmonary capillary wedge pressure, were identical.",
"     </li>",
"     <li>",
"      In a similarly designed trial of 10 patients with lactic acidosis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mmol/kg)",
"      </span>",
"      and an equivalent dose of sodium chloride were administered in random order [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/13\">",
"       13",
"      </a>",
"      ]. Bicarbonate therapy significantly increased the arterial pH (from 7.16 to 7.21) and serum bicarbonate (from 16 to 19",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Again, the infusion of sodium bicarbonate and sodium chloride produced similar changes in cardiac output, mean arterial pressure, and pulmonary artery pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two trials were too small to detect a minor benefit of bicarbonate therapy; in addition, patients with severe acidemia were not represented. Thus, we and other experts continue to use bicarbonate therapy in patients who have an arterial pH less than 7.10. However, bicarbonate therapy requires adequate ventilation as discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link&amp;anchor=H12631806#H12631806\">",
"     \"Bicarbonate therapy in lactic acidosis\", section on 'Potential harms of bicarbonate, and alterative agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who are receiving bicarbonate for the treatment of severe organic acidosis, we initiate dialysis for those who have an ongoing and increasing demand for bicarbonate to maintain pH despite administered bicarbonate even if volume overload is not present. However there are no published data to suggest that a survival benefit associated with this approach. Thus, some clinicians would favor continuing bicarbonate administration providing there are no other indications for dialysis, and some would favor just treating the underlying disease process that caused the acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with AKI, bicarbonate administration may be associated with serious side effects. Bicarbonate administration may cause a decrease in the level of ionized or free calcium level because of a pH-dependent increase in the binding of calcium to albumin. This could cause or worsen the symptoms of hypocalcemia since symptoms of hypocalcemia reflect from the ionized, not total, calcium. (See",
"    <a class=\"local\" href=\"#H6570685\">",
"     'Hypocalcemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As in patients without AKI, bicarbonate administration could cause hypernatremia, an increase in the partial pressure of carbon dioxide (pC02) among patients with circulatory or ventilatory compromise, and increased intracranial pressure in patients with diabetic ketoacidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6570685\">",
"    <span class=\"h2\">",
"     Hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum calcium levels should be closely followed among patients with AKI. Hypocalcemia is common among such patients and is primarily related to increases in serum phosphorus levels caused by reduced GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Other contributors to hypocalcemia include skeletal resistance to parathyroid hormone and decreased synthesis of 1,25(OH)2D3. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24984?source=see_link\">",
"     \"Etiology of hypocalcemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum ionized calcium should be measured in addition to the total serum calcium if a laboratory known to reliably measure ionized calcium is available. The total serum calcium concentration does not accurately reflect the ionized calcium concentration among patients with low or high serum albumin levels since calcium is bound to albumin. In addition, since the binding of calcium to albumin is pH-dependent, the amount of free calcium may be altered by acid-base disorders or by the rapid correction of such disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34005?source=see_link\">",
"     \"Diagnostic approach to hypocalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23685?source=see_link\">",
"     \"Relation between total and ionized serum calcium concentration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of hypocalcemia depends on the severity and presence of symptoms. If the patient is asymptomatic and hyperphosphatemia is present, initial therapy is the correction of hyperphosphatemia. The reduction of serum phosphate as a result of treatment with oral phosphate binders is often sufficient to improve the serum calcium. (See",
"    <a class=\"local\" href=\"#H6570714\">",
"     'Hyperphosphatemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Symptomatic patients should be more aggressively treated with intravenous calcium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link\">",
"     \"Treatment of hypocalcemia\"",
"    </a>",
"    .) However, the administration of calcium to patients who are severely hyperphosphatemic may result in the deposition of calcium phosphate into vasculature and organs. Patients with symptomatic hypocalcemia in the presence of serum phosphorus levels &gt;8 to 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6 to 3.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    should be dialyzed to correct both hyperphosphatemia and hypocalcemia. Among such patients we generally use high calcium dialysate.",
"   </p>",
"   <p>",
"    Occasionally patients will develop life-threatening symptoms of hypocalcemia while awaiting dialysis. Such patients should be treated with intermittent intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15799?source=see_link\">",
"     calcium chloride",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    , even though there is a risk of metastatic calcification associated with such therapy. We treat with intravenous calcium patients with symptoms of hypocalcemia including paresthesias, tetany (especially carpopedal spasm), confusion, seizures, Trousseau&rsquo;s sign (carpal spasm occurring after the occlusion of the brachial artery with a blood pressure cuff for three minutes), Chvostek&rsquo;s sign (contraction of the facial muscle in response to tapping the facial nerve anterior to the ear), or QT prolongation. Initially, intravenous calcium (1 to 2 g of calcium gluconate, equivalent to 90 to 180 mg elemental calcium, in 50 mL of 5 percent dextrose) can be infused over 10 to 20 minutes. The calcium should not be given more rapidly, because of the risk of serious cardiac dysfunction, including systolic arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/22\">",
"     22",
"    </a>",
"    ]. This dose of calcium gluconate will raise the serum calcium concentration for only two or three hours while arrangements for dialysis are made. Either 10 percent calcium gluconate (90 mg of elemental calcium per 10 mL) or 10 percent calcium chloride (270 mg of elemental calcium per 10 mL) can be used to prepare the infusion solution. Calcium gluconate is usually preferred because it is less likely to cause tissue necrosis if extravasated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of hypocalcemia\", section on 'Intravenous calcium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6570714\">",
"    <span class=\"h2\">",
"     Hyperphosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperphosphatemia is observed in many patients with AKI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13527?source=see_link\">",
"     \"Overview of the causes and treatment of hyperphosphatemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=see_link\">",
"     \"Acute phosphate nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally treat with dietary phosphate binders all patients with AKI who have moderately to severely elevated serum phosphate concentrations (ie, &gt;6",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    although there are no published data that have shown that the treatment of acute hyperphosphatemia related to AKI improves outcomes. We do not treat patients with mild hyperphosphatemia (ie 4.5 to 6",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    that is due to AKI.",
"   </p>",
"   <p>",
"    The selection of phosphate binder depends on the level of serum ionized calcium concentration. If the serum ionized calcium concentration is low, calcium-containing phosphate binders such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=see_link\">",
"     calcium acetate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    may be given to control serum phosphate levels, providing patients can take oral medications. If the serum ionized calcium concentration is high, noncalcium phosphate binders such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/37/28244?source=see_link\">",
"     lanthanum carbonate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    or Al(OH)3 should be given. Among such patients, noncalcium binders are preferred in order to prevent increases in the",
"    <span class=\"nowrap\">",
"     calcium/phosphate",
"    </span>",
"    product. However there are no data that have compared outcomes among patients treated with different agents in the setting of AKI. The use of Al(OH)3 should be limited to several days to minimize accumulation of aluminum.",
"   </p>",
"   <p>",
"    There are no specific guidelines at which level to initiate hemodialysis in the setting of hyperphosphatemia, and the decision to initiate hemodialysis is often based upon concomitant clinical and laboratory findings (such as oliguria, development of hypervolemia, hyperkalemia, etc). We generally dialyze patients with severe hyperphosphatemia (defined as &gt;12",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    since dialysis works more rapidly than phosphate binders and thus may be more effective in preventing injury due to the precipitation of calcium and phosphate. As noted above, we also dialyze patients with less severe hyperphosphatemia (serum phosphorus levels defined as &gt;8 to 10",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    who have symptomatic hypocalcemia. Dialysis may also be used in patients who are unable to take oral medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6570782\">",
"    <span class=\"h2\">",
"     Bleeding disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKI can cause a qualitative platelet dysfunction that results in a hemorrhagic diathesis. The major clinical manifestation of this is cutaneous bleeding, but gastrointestinal bleeding can also occur. In the absence of symptoms, platelet function is generally not assessed in patients with AKI. The clinical manifestations, indications for treatment, and modes of therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H134900926\">",
"    <span class=\"h2\">",
"     Indications for dialysis therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accepted indications for dialysis in patients with AKI generally include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid overload that is refractory to diuretics.",
"     </li>",
"     <li>",
"      Hyperkalemia (serum potassium concentration &gt;6.5",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      or rapidly rising potassium levels, refractory to medical therapy.",
"     </li>",
"     <li>",
"      Metabolic acidosis (pH less than 7.1) in patients in whom the administration of bicarbonate is not indicated, such as those with volume overload (who would not tolerate the obligate sodium load), or those with lactic acidosis or ketoacidosis in whom bicarbonate administration has not been shown to be effective.",
"     </li>",
"     <li>",
"      Signs of uremia, such as pericarditis, neuropathy, or an otherwise unexplained decline in mental status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Non-emergent dialysis may also be indicated for patients with prolonged AKI even in the absence of the indications listed above. The optimal time to start dialysis is not known and the BUN is only one of multiple parameters that may be used to assess dialysis requirement. The optimal timing of the initiation of dialysis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6570813\">",
"    <span class=\"h1\">",
"     NUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major goals of nutritional support for critically ill patients with AKI are to provide adequate amounts of energy, protein, and nutrients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nutritional requirements are dependent on the severity of the underlying disease, preexisting nutritional status, and comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link&amp;anchor=H12#H12\">",
"     \"Nutrition support in critically ill patients: An overview\", section on 'Nutritional requirements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although requirements vary based upon the underlying catabolic state, some investigators feel that patients need approximately 25 to 30",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day. Others, however, feel that permissive underfeeding may actually be a preferred approach [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/24\">",
"     24",
"    </a>",
"    ], despite the lack of specific data on underfeeding in AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link&amp;anchor=H14#H14\">",
"     \"Nutrition support in critically ill patients: An overview\", section on 'Calories'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protein energy wasting is common among critically ill patients with AKI and contributes to mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/26\">",
"     26",
"    </a>",
"    ]. Protein requirement increases with the severity of the underlying illness and with initiation of dialysis. Whereas nondialysis patients with only mild to moderate illness require only 0.8 to 1.2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day, critically ill patients or patients who are on dialysis generally require 1.2 to 1.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day or more [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link&amp;anchor=H15#H15\">",
"     \"Nutrition support in critically ill patients: An overview\", section on 'Protein'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Providing adequate nutrition to patients with AKI who require dialysis may necessitate parenteral or enteral nutrition. Among critically ill patients without AKI, most clinicians feel that enteral nutrition should be employed in preference to parenteral nutrition whenever possible because of its lower cost, less frequent and severe complications, less mucosal permeability, greater wound healing, and lower rates of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with AKI, there are limited data concerning the efficacy and safety of enteral nutrition. In one study, enteral nutrition-related outcomes were compared among 247 consecutive patients fed enterally: 114 required dialysis; 68 had AKI but did not require dialysis; and 65 had normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/28\">",
"     28",
"    </a>",
"    ]. Other than an increased incidence of nasogastric tube obstruction and high gastric residual volumes among dialyzed patients, there was no difference in gastrointestinal and mechanical complications in the three groups. The mean amount of nonprotein and protein calories for dialyzed patients were 23.4",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    and 0.92",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    respectively, with the amount of delivered protein calories being slightly less than recommended. This can be overcome by administering parenteral amino acids during daily dialysis.",
"   </p>",
"   <p>",
"    There are few good studies that have evaluated the safety and efficacy of parenteral nutrition among patients with AKI. A Cochrane review was unable to show an overall benefit of parenteral nutrition on survival but was limited by poor quality of available studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6570915\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data to guide the frequency with which serum electrolytes, pH, phosphate and calcium should be checked. In otherwise stable, we generally check serum potassium, sodium, and bicarbonate twice daily even if initial values are normal since, as discussed above, the initial creatinine may not reflect the true degree of kidney dysfunction. In the setting of a GFR of zero, a dangerous increase in serum potassium may result from relatively small shifts of potassium from the intracellular to extracellular compartment or from small amounts of potassium ingested in the diet. Serum potassium should be checked more frequently in patients who have an elevated serum potassium on presentation or who are oliguric or hemodynamically unstable.",
"   </p>",
"   <p>",
"    Total serum calcium, phosphate, and albumin should be measured daily in stable patients. The serum calcium should be measured more frequently (twice daily) in patients who require calcium or bicarbonate.",
"   </p>",
"   <p>",
"    It is important to carefully monitor daily weights, fluid intake and urine output in order to assess daily fluid balance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30425/abstract/30\">",
"     30",
"    </a>",
"    ]. In critically ill patients who are incontinent or otherwise unable to monitor urine output due to compromised mental status, an indwelling catheter may be necessary to ensure accurate measurement of urine output. The risks of an indwelling catheter primarily include infection and must be weighed against the potential benefit in each patient. This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24600525\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with AKI recover renal function with recovery manifested by an increase in urine output and a gradual decrease of the BUN and serum creatinine concentration. However many patients, including those with previously normal renal function, do not return to baseline renal function. In addition, many studies have demonstrated an increase in the risk of chronic kidney disease (CKD) and end stage renal disease (ESRD) among patients who recover from AKI. Even small acute rises in serum creatinine as low as 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (27",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    are associated with both short-term and long-term increases in mortality. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=see_link\">",
"     \"Renal and patient outcomes after acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6570934\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute kidney injury (AKI) is an abrupt decline in kidney function that results in an elevation of serum blood urea nitrogen (BUN), creatinine, and other metabolic waste products that are normally excreted by the kidney. (See",
"      <a class=\"local\" href=\"#H6569973\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potentially life-threatening complications of AKI include volume overload, hyperkalemia, acidosis, and uremia. (See",
"      <a class=\"local\" href=\"#H6570002\">",
"       'Immediate therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Volume status should be assessed in all patients with AKI. Fluid should be given to restore intravascular volume in patients who are volume depleted. The amount of administered fluid and the rate of replacement should be targeted to defined endpoints such as mean arterial pressure. Types of replacement fluid include colloid- and crystalloid solutions-containing solutions. For patients with AKI who require replacement fluid, we generally use non-potassium-containing crystalloid solution such as normal saline rather than colloid-containing solutions. (See",
"      <a class=\"local\" href=\"#H6570009\">",
"       'Volume issues'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link\">",
"       \"Maintenance and replacement fluid therapy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diuretics should not be used for prolonged therapy in place of dialysis. Diuretics may be used for a limited period of time to relieve signs and symptoms of volume overload Loop diuretics may be more effective than thiazides at glomerular filtration rate less than 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2. (See",
"      <a class=\"local\" href=\"#H6570023\">",
"       'Volume overload'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of hyperkalemia is determined by severity and presence of any associated signs such as electrocardiographic changes or peripheral neuromuscular abnormalities. The treatment of hyperkalemia includes both medical therapy and dialysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=see_link\">",
"       \"Clinical manifestations of hyperkalemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic acidosis is common among patients with AKI. In general we dialyze patients with AKI who are volume overloaded and have a pH &lt;7.1",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Dialysis is preferred to the administration of bicarbonate among such patients because bicarbonate administration results in a large sodium load that may cause or contribute to volume overload.",
"      <br/>",
"      <br/>",
"      Among patients with AKI who are not volume overloaded and have no other indication for acute dialysis, bicarbonate may be used in the setting of a non-anion gap acidosis related to diarrhea, or in patients with a severe organic acidosis while awaiting dialysis. We do not use bicarbonate therapy in patients with a less severe organic acidosis (pH 7.1 or greater). (See",
"      <a class=\"local\" href=\"#H6570037\">",
"       'Metabolic acidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperphosphatemia and hypocalcemia are commonly observed in patients with AKI. The treatment depends on the degree of hyperphosphatemia and the presence or absence of symptoms from hypocalcemia. (See",
"      <a class=\"local\" href=\"#H6570714\">",
"       'Hyperphosphatemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We treat with dietary phosphate binders all patients with AKI who have moderately to severely elevated serum phosphate concentrations (ie, &gt;6",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"      We do not treat patients with mild hyperphosphatemia (ie, 4.5 to 6",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      that is due to AKI.",
"     </li>",
"     <li>",
"      We generally dialyze patients with severe hyperphosphatemia (defined as &gt;12",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.9",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      We dialyze patients with less severe hyperphosphatemia (serum phosphorus levels defined as &gt;8 to 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.6 to 3.2",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      who have symptomatic hypocalcemia.",
"     </li>",
"     <li>",
"      Dialysis may also be used in patients who are unable to take oral medication.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/1\">",
"      Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/2\">",
"      Kidney Int Suppl 2012; 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/3\">",
"      Bagshaw SM, Bellomo R, Kellum JA. Oliguria, volume overload, and loop diuretics. Crit Care Med 2008; 36:S172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/4\">",
"      Grams ME, Estrella MM, Coresh J, et al. Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol 2011; 6:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/5\">",
"      Goldstein SL, Somers MJ, Baum MA, et al. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 2005; 67:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/6\">",
"      Payen D, de Pont AC, Sakr Y, et al. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008; 12:R74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/7\">",
"      Bouchard J, Soroko SB, Chertow GM, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009; 76:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/8\">",
"      Kraut JA, Kurtz I. Use of base in the treatment of severe acidemic states. Am J Kidney Dis 2001; 38:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/9\">",
"      Marsh JD, Margolis TI, Kim D. Mechanism of diminished contractile response to catecholamines during acidosis. Am J Physiol 1988; 254:H20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/10\">",
"      Mitchell JH, Wildenthal K, Johnson RL Jr. The effects of acid-base disturbances on cardiovascular and pulmonary function. Kidney Int 1972; 1:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/11\">",
"      Teplinsky K, O'Toole M, Olman M, et al. Effect of lactic acidosis on canine hemodynamics and left ventricular function. Am J Physiol 1990; 258:H1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/12\">",
"      Orchard CH, Kentish JC. Effects of changes of pH on the contractile function of cardiac muscle. Am J Physiol 1990; 258:C967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/13\">",
"      Mathieu D, Neviere R, Billard V, et al. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med 1991; 19:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/14\">",
"      Orchard CH, Cingolani HE. Acidosis and arrhythmias in cardiac muscle. Cardiovasc Res 1994; 28:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/15\">",
"      Kraut JA, Madias NE. Treatment of acute metabolic acidosis: a pathophysiologic approach. Nat Rev Nephrol 2012; 8:589.",
"     </a>",
"    </li>",
"    <li>",
"     MB, HMG. Metabolic Acidosis. In: Fluid, Electrolyte and Acid-Base Physiology, WB Saunders, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/17\">",
"      Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/18\">",
"      Cooper DJ, Walley KR, Wiggs BR, Russell JA. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med 1990; 112:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/19\">",
"      Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med 2001; 344:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/20\">",
"      Massry SG, Stein R, Garty J, et al. Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of 1,25 (OH)2 D3. Kidney Int 1976; 9:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/21\">",
"      Massry SG, Arieff AI, Coburn JW, et al. Divalent ion metabolism in patients with acute renal failure: studies on the mechanism of hypocalcemia. Kidney Int 1974; 5:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/22\">",
"      Tohme, JF, Bilezikian, JP. Diagnosis and treatment of hypocalcemic emergencies. The Endocrinologist 1996; 6:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/23\">",
"      Fiaccadori E, Cremaschi E. Nutritional assessment and support in acute kidney injury. Curr Opin Crit Care 2009; 15:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/24\">",
"      Krishnan JA, Parce PB, Martinez A, et al. Caloric intake in medical ICU patients: consistency of care with guidelines and relationship to clinical outcomes. Chest 2003; 124:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/25\">",
"      Bellomo R, Seacombe J, Daskalakis M, et al. A prospective comparative study of moderate versus high protein intake for critically ill patients with acute renal failure. Ren Fail 1997; 19:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/26\">",
"      Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/27\">",
"      McClave SA, Martindale RG, Vanek VW, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009; 33:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/28\">",
"      Fiaccadori E, Maggiore U, Giacosa R, et al. Enteral nutrition in patients with acute renal failure. Kidney Int 2004; 65:999.",
"     </a>",
"    </li>",
"    <li>",
"     Li, Y, Tang, X, Zhang, J, Wu, T. Nutritional support for acute kidney injury. Cochrane Database Syst Rev 2010; :CD005426.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30425/abstract/30\">",
"      Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365:417.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14035 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30425=[""].join("\n");
var outline_f29_45_30425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6570934\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6569973\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2271117744\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6569987\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2271118042\">",
"      INITIAL EVALUATION AFTER DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6569994\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6570002\">",
"      Immediate therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6570009\">",
"      Volume issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6570016\">",
"      - Volume depletion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6570023\">",
"      - Volume overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6570030\">",
"      Hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6570037\">",
"      Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6570685\">",
"      Hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6570714\">",
"      Hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6570782\">",
"      Bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H134900926\">",
"      Indications for dialysis therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6570813\">",
"      NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6570915\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24600525\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6570934\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=related_link\">",
"      Acute phosphate nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35223?source=related_link\">",
"      Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44456?source=related_link\">",
"      Cardiorenal syndrome: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=related_link\">",
"      Clinical manifestations of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=related_link\">",
"      Crush-related acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=related_link\">",
"      Definition of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34005?source=related_link\">",
"      Diagnostic approach to hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24984?source=related_link\">",
"      Etiology of hypocalcemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13527?source=related_link\">",
"      Overview of the causes and treatment of hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=related_link\">",
"      Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23685?source=related_link\">",
"      Relation between total and ionized serum calcium concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=related_link\">",
"      Renal and patient outcomes after acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/40/650?source=related_link\">",
"      Treatment of refractory edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_45_30426="Management of locoregional recurrence of breast cancer after mastectomy";
var content_f29_45_30426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of locoregional recurrence of breast cancer after mastectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30426/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30426/contributors\">",
"     Ariel Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30426/contributors\">",
"     Lisa A Kachnic, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30426/contributors\">",
"     Michael S Sabel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30426/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30426/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30426/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/45/30426/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30426/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/45/30426/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/45/30426/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following mastectomy for operable breast cancer, disease can recur locally, regionally,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    at distant metastatic sites. A local recurrence is defined as reappearance of cancer on the ipsilateral chest wall. In contrast, a regional recurrence denotes tumor involving the regional lymph nodes, usually ipsilateral axillary or supraclavicular, less commonly infraclavicular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    internal mammary nodes.",
"   </p>",
"   <p>",
"    Treatment has the potential to provide long-term disease control for patients who develop an isolated locoregional recurrence after mastectomy. However, the management of these patients is complex and usually requires multidisciplinary assessment and planning.",
"   </p>",
"   <p>",
"    The management of a locoregional recurrence after mastectomy for operable breast cancer will be reviewed here. The management of a local recurrence after breast conserving therapy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34650?source=see_link\">",
"     \"Management of locoregional recurrence of breast cancer after breast conserving therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 to 10 percent of patients undergoing mastectomy for operable breast cancer will have a chest wall or regional nodal recurrence within 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. The risk of a postmastectomy locoregional recurrence is slightly lower than that after breast conserving therapy (BCT, 10 to 15 percent), although it is much higher in women who undergo breast conserving surgery without radiation therapy (RT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link\">",
"     \"Role of radiation therapy in breast conservation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also differences in the time course, clinical features, and prognosis of a locoregional recurrence after mastectomy as compared to BCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrences tend to occur earlier after mastectomy (median two to three years versus three to four years after BCT) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/8-10\">",
"       8-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most postmastectomy local recurrences are diagnosed by physical examination, and due to anatomical changes after mastectomy, the role of imaging is less clear.",
"     </li>",
"     <li>",
"      Although some data sets describe a similar overall prognosis for locoregional disease recurrence after mastectomy as compared to BCT [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/8\">",
"       8",
"      </a>",
"      ], postmastectomy recurrences are more likely to involve regional nodes, and these cases are associated with higher rates of simultaneous distant metastases and poorer cause-specific survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Distribution and time course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 50 and 70 percent of postmastectomy locoregional recurrences are isolated to the chest wall. Thirty to 40 percent have a local plus regional recurrence in the supraclavicular, axillary, or internal mammary nodes, with the supraclavicular nodes being the most common site. This distribution may change with the more widespread use of SLN biopsy.",
"   </p>",
"   <p>",
"    There is wide variability in the reported incidence of simultaneous locoregional and distant metastases (10 to 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/2,5,6,11-14\">",
"     2,5,6,11-14",
"    </a>",
"    ]. However, it is generally thought that approximately one-third of patients who present with a postmastectomy locoregional recurrence have synchronous distant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, a thorough restaging evaluation should be undertaken prior to definitive local therapy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Staging workup'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The median interval to a locoregional recurrence after mastectomy is two to three years, and 90 percent arise within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/1,4,6,15-18\">",
"     1,4,6,15-18",
"    </a>",
"    ]. Recurrence may be delayed in patients with hormone receptor-positive disease who receive adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/13,19\">",
"     13,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major risk factors for a postmastectomy local recurrence are the number of positive axillary lymph nodes and the size of the primary tumor. Axillary recurrence rates are consistently over 20 percent in women with &ge;4 positive nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/20\">",
"     20",
"    </a>",
"    ]. The combined use of tumor size and extent of nodal disease may permit a better prediction of the likelihood of locoregional recurrence.",
"   </p>",
"   <p>",
"    Other factors that may help to predict for locoregionally recurrent disease include age at diagnosis, hormone receptor status, the presence of lymphovascular invasion or extracapsular nodal extension, and positive deep margins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link&amp;anchor=H4#H4\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Risk factors for locoregional recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Impact of postmastectomy chest wall irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmastectomy chest wall irradiation reduces the rate of chest wall recurrence by 65 to 75 percent, and in high-risk women, it also improves survival. In modern randomized trials, rates of locoregional recurrence in women receiving postmastectomy RT are 8 to 13 percent compared to 30 to 35 percent in the nonirradiated control groups [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/11,23\">",
"     11,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link&amp;anchor=H14#H14\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Modern clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical practice guidelines from major groups recommend postmastectomy RT for patients with tumor size greater than 5 cm, four or more positive axillary lymph nodes, as well as for those with positive surgical margins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. For patients with one to three positive nodes, the role of postmastectomy chest wall irradiation is controversial. This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link&amp;anchor=H18#H18\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND PRETREATMENT EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Presenting signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A postmastectomy locoregional recurrence is usually detected clinically as a mass or multiple nodules in the chest wall or overlying skin in or near the mastectomy scar, or in the skin flaps. The skin of the chest wall may also be diffusely involved with inflammatory changes without a discernible mass. The term \"carcinoma en cuirasse\" refers to a distinct form of local recurrence in which there is diffuse infiltration of the skin or subcutaneous tissues of the chest wall, with woody induration and spread of tumor often beyond the limits of standard surgical or radiation boundaries. Nodules and ulceration are often present.",
"   </p>",
"   <p>",
"    The first clinical manifestation of a postmastectomy regional recurrence may be an asymptomatic mass in the axilla or the supraclavicular fossa [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/28\">",
"     28",
"    </a>",
"    ]. A regional recurrence may also present with pain in either location, or the new onset of brachial plexopathy or lymphedema of the arm. These may occur in the absence of palpable adenopathy. Any patient with new onset of lymphedema after breast cancer treatment should be evaluated for a regional recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Solitary \"sternal metastases\" may actually represent direct extension of involved internal mammary nodes. Such patients should be carefully imaged to adequately assess this distinction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35831?source=see_link&amp;anchor=H20#H20\">",
"     \"Metastatic breast cancer: Local treatment\", section on 'Bone metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Findings on imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common mammographic findings in TRAM-reconstructed breasts include calcifications that are believed to indicate fat necrosis, benign dermal calcifications, calcified hematomas, clustered microcalcifications, and areas of increased or decreased density without calcifications that appear related to surgical changes and fat necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mammographic (and MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/33\">",
"     33",
"    </a>",
"    ]) appearance of recurrent carcinoma in TRAM flaps has been described in small series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. In general, the findings appear to parallel those in the intact breast, although there is not enough experience to know whether sensitivity and specificity are comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest experience of eight local recurrences that developed in six women following mastectomy and TRAM reconstruction, all were detected mammographically, six with a mass (two with calcifications) and two with isolated pleomorphic calcifications [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second report from the same institution included 106 patients who underwent serial mammographic surveillance after mastectomy and TRAM reconstruction for cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/34\">",
"       34",
"      </a>",
"      ]. Over a two-year period, there were seven suspicious or highly suggestive mammographic findings (BI-RADS 4 or 5, (",
"      <a class=\"graphic graphic_table graphicRef66601 \" href=\"UTD.htm?38/19/39227\">",
"       table 1",
"      </a>",
"      )), two of which were shown to be invasive cancers, one detected by mammography alone. The mammographic features in these two patients were a mass with irregular margins adjacent to the pectoral muscle and a mass with spiculated margins in the extreme upper outer quadrant of the breast. One additional cancer was later diagnosed in a patient who had a BI-RADS 3 finding, which was considered a false-negative study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of a local chest wall recurrence includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonmalignant postradiation or postoperative change",
"     </li>",
"     <li>",
"      Foreign body cyst around suture material",
"     </li>",
"     <li>",
"      Cellulitis",
"     </li>",
"     <li>",
"      A bony nodule on a rib or costal cartilage from surgical trauma",
"     </li>",
"     <li>",
"      In patients who have been reconstructed with a myocutaneous flap, areas of fat necrosis can mimic a local disease recurrence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link\">",
"       \"Breast reconstruction in women with breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A radiation-induced sarcoma of the bone or soft tissues of the chest wall, although these are rare, and they typically appear later, at a median of 10 years posttreatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=see_link\">",
"       \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine needle aspiration (FNA) biopsy is a simple and accurate method for differentiating scar from recurrent carcinoma. However, tissue biopsy (typically a core needle biopsy) is usually necessary not only to confirm the diagnosis of a local recurrence, but also to assay the tumor tissue for hormone receptors and HER2 overexpression, factors which influence treatment decisions regarding adjuvant systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link\">",
"     \"HER2 and predicting response to therapy in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=see_link\">",
"     \"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Staging workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have a postmastectomy locoregional recurrence should undergo complete restaging evaluation to rule out distant metastases. At a minimum, this should include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood tests, including a complete blood count and liver function tests",
"     </li>",
"     <li>",
"      Radionuclide bone scan, even in asymptomatic patients, as bone is the most common site of metastatic disease",
"     </li>",
"     <li>",
"      CT of the chest, abdomen, and pelvis to screen for sites of metastatic disease. The most common site of unsuspected disease is in the internal mammary lymph nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/40\">",
"       40",
"      </a>",
"      ]. Chest CT is also be useful to differentiate recurrent tumor in the chest wall, subcutaneous fat, pectoralis muscles and brachial plexus from postoperative and postradiation change [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients who have symptoms of a brachial plexopathy or arm edema without obvious adenopathy, contrast-enhanced MRI can help in the distinction between tumor recurrence versus radiation-induced fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link&amp;anchor=H4#H4\">",
"       \"Complications of peripheral nerve irradiation\", section on 'Late-delayed brachial plexopathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Positron emission tomography (PET) scans and integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    are being used more frequently to survey for distant metastases in patients with recurrent breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/44-51\">",
"     44-51",
"    </a>",
"    ]. PET scans are more sensitive than conventional imaging such as CT, and the detection of unsuspected metastatic disease often alters the therapeutic plan. However, PET scans also have a high false positive rate (approximately 11 percent in a pooled analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/49\">",
"     49",
"    </a>",
"    ]), which may lead to additional imaging studies and biopsies.",
"    <br/>",
"    <br/>",
"    There is no consensus on whether PET scans should be considered a standard component of the restaging evaluation in women with a suspected locoregional recurrence. In guidelines from the National Comprehensive Cancer Network (NCCN), PET is described as \"optional\" for the restaging evaluation of women with suspected locoregionally recurrent breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/26\">",
"     26",
"    </a>",
"    ]. In the opinion of the authors, PET and integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scans should be used selectively, with tissue confirmation of distant disease before altering the treatment plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients treated for a locoregional recurrence after mastectomy, the most consistently documented prognostic factor is the interval between initial diagnosis and recurrence. In most series, a disease-free interval of at least two years is associated with a significantly better outcome as compared to shorter durations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/1,5,8,15,18,28,52-55\">",
"     1,5,8,15,18,28,52-55",
"    </a>",
"    ]. In a representative report of 230 women with a chest wall or regional nodal recurrence, five-year survival rates were 50 and 35 percent for patients with a disease-free interval of two or more versus less than two years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term local control and overall survival rates are also dependent upon the site and volume of the disease recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/15,18,54\">",
"     15,18,54",
"    </a>",
"    ]. In general, the greater the disease volume, the lower the likelihood of achieving long-term local control and relapse-free survival.",
"   </p>",
"   <p>",
"    Control of a diffuse inflammatory recurrence is more difficult than if disease is limited to an isolated nodule. This difference may reflect surgical resectability of the recurrent disease. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Surgical resection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In most series, local control rates are highest with either limited chest wall or axillary node involvement and lower when there is both local and regional recurrence, particularly if the supraclavicular nodes are involved. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Treatment of regional axillary and/or supraclavicular recurrence'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a series of 145 patients undergoing RT for a postmastectomy locoregional recurrence, five-year survival rates according to the site of disease recurrence were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chest wall alone &mdash; 52 percent",
"     </li>",
"     <li>",
"      Axilla alone &mdash; 50 percent",
"     </li>",
"     <li>",
"      Supraclavicular nodes alone &mdash; 28 percent",
"     </li>",
"     <li>",
"      Chest wall plus axilla &mdash; 28 percent",
"     </li>",
"     <li>",
"      Supraclavicular nodes plus chest",
"      <span class=\"nowrap\">",
"       wall/axilla",
"      </span>",
"      &mdash; 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who develop a chest wall recurrence after having an initially node-negative breast cancer do better than those who presented with node-positive disease, particularly if more than three nodes were involved [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/15,56\">",
"     15,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     GENERAL TREATMENT PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A locoregional recurrence after mastectomy represents a difficult clinical problem, and there is little consensus on how best to manage these patients. Major issues include the lack of randomized trials to guide treatment and the marked evolution in the management of earlier stage disease over the last decade that has implications for evaluation and management of locoregional recurrence. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the past, nearly all patients with recurrent disease had already undergone ALND as a component of upfront therapy. At present, many women have undergone SLN biopsy which, if negative, was not followed by ALND. This has implications for the need to restage the axilla at the time of recurrence and for management of the axilla in the face of an axillary regional recurrence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"       \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because of the increasing use of postmastectomy chest wall irradiation, many chest wall recurrences will be in previously irradiated women, whereas in the past, this was a less frequent scenario. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link\">",
"       \"Postmastectomy chest wall irradiation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decisions on local therapy are often altered by whether the patient will have systemic treatment, and in some cases, by the response to such therapy. For some patients (eg, those with an apparently isolated supraclavicular nodal recurrence or a chest wall recurrence that would require a large resection), it is preferable to administer systemic therapy first, not only to facilitate successful locoregional treatment, but also to be certain that early evidence of distant metastases does not emerge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because optimal management of these patients typically requires combined modality therapy, multidisciplinary assessment and planning is essential. We prefer these patients be presented to a multidisciplinary breast cancer tumor board for formal review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT OF AN ISOLATED CHEST WALL RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined modality treatment has the potential to provide long-term disease control for some patients with an isolated chest wall recurrence. However, even if distant metastases are already present, optimal locoregional treatment can significantly reduce the morbidity of uncontrolled local spread.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, we prefer a wide local excision for solitary or multiple nodules that are amenable to resection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/2,15,17,57\">",
"     2,15,17,57",
"    </a>",
"    ]. For patients who are candidates for radiation therapy (RT), surgical resection reduces the required dose of chest wall RT and maximizes the likelihood of long-term disease control. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Subsequent chest wall recurrences are less frequent in patients who undergo complete excision, compared to those who are left with gross residual disease after surgery (21 versus 60 percent in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/18\">",
"     18",
"    </a>",
"    ]). Skin grafts or rotational flaps, such as a latissimus dorsi flap, may be necessary after complete excision. In some cases, chest wall resection and reconstruction may be necessary in order to obtain negative margins. However, extensive surgery for locally recurrent disease should only be performed if other options are not available and if functional morbidity can be minimized [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. In such cases, initial treatment with systemic therapy is preferable, not only to facilitate successful locoregional treatment, but also to be certain that early evidence of distant metastases does not emerge. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Systemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The incidence of a second local recurrence with wide local excision alone is 60 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/55,61\">",
"     55,61",
"    </a>",
"    ]. As a result, most patients who did not receive immediate postmastectomy chest wall irradiation are recommended to undergo RT in addition to surgery for a chest wall recurrence, even if negative margins are achieved. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Better results have been reported with more extensive surgery (very wide local excision of skin and subcutaneous tissue with partial or full thickness chest wall resection) without RT in highly selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. The likelihood of local control after surgery alone is highest when the recurrence pattern is a single as compared to multiple nodules and for patients whose relapse-free interval is longer than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/58,65-68\">",
"     58,65-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Management of the axilla",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the approach to managing the axilla in patients who have a postmastectomy chest wall recurrence is evolving. Because of the increasing use of SLN biopsy, many women will have intact axillary nodes unless the initial SLN was positive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Axillary evaluation should begin with a thorough physical examination and ultrasound of the axilla, with FNA biopsy of any clinically suspicious lymph nodes. If there is clinical evidence of axillary regional disease, a formal level I and II ALND (if the patient previously had SLN biopsy alone) or axillary exploration with resection (if an ALND was previously performed) is warranted.",
"   </p>",
"   <p>",
"    If the patient had a complete ALND initially and has no clinical evidence of regional disease, it is not necessary to reexplore the axilla.",
"   </p>",
"   <p>",
"    There is no consensus as to the need for repeat axillary staging and the type of procedure (ALND or reoperative SLN biopsy) that should be done in the setting of a postmastectomy chest wall recurrence and a clinically negative axilla in a patient who previously did not have an ALND [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/69\">",
"     69",
"    </a>",
"    ]. There is no single recommendation that can be made for all such patients. The decision may best be addressed in the context of a multidisciplinary discussion. Factors to take into account include previous axillary surgery or radiation therapy, the initial disease stage and likelihood of distant metastases, the pathology of the recurrence (in situ versus invasive) and the impact that the identification of regional disease will have on adjuvant therapy decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT is an integral part of treatment of women with a locoregional breast cancer recurrence. However, the RT approach depends on whether immediate postmastectomy RT was administered (after the initial diagnosis of breast cancer).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1494193792\">",
"    <span class=\"h3\">",
"     No prior RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who did not undergo immediate postmastectomy radiation therapy (RT), external beam RT is a standard treatment for an isolated postmastectomy chest wall recurrence. Outcomes from several retrospective series in which the majority of patients underwent excision followed by RT are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef76755 \" href=\"UTD.htm?21/40/22157\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/8,16-18,28,52,53,57,70-72\">",
"     8,16-18,28,52,53,57,70-72",
"    </a>",
"    ]. Optimal RT management generally involves treatment to the entire chest wall and draining lymph node areas, even if the recurrence is localized to a small area of the chest wall. Limited treatment of the chest wall increases the risk for future recurrences in the supraclavicular and axillary regions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/15,18,57,73\">",
"     15,18,57,73",
"    </a>",
"    ]. The RT techniques usually employed are similar to those used for newly diagnosed breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link&amp;anchor=H12#H12\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\", section on 'Treatment techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, long-term local control is achieved in 42 to 86 percent of patients, and the five and ten-year overall survival rates range from 35 to 82 and 26 to 62 percent, respectively. Unfortunately, only about one-third of treated patients remain free from distant metastases at five years.",
"   </p>",
"   <p>",
"    For patients who have a categorically unresectable chest wall recurrence, reirradiation alone is sometimes attempted. While response rates with RT are high after a less than excisional biopsy (73 percent or higher), approximately 60 to 70 percent will experience a second local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/16,18,52,61\">",
"     16,18,52,61",
"    </a>",
"    ]. Because of the high risk of a second recurrence in these patients, we prefer systemic therapy as initial management using an approach similar to that for patients with metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Management of previously irradiated women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of women who recur in the chest wall after a course of immediate postmastectomy chest wall RT is less clear. Full dose reirradiation of the chest wall is generally not considered because of concerns for long-term toxicity. However, if there are no other viable options, retreatment of at least limited volumes with decreased total radiation doses may be recommended in such patients to maximize the opportunity for local control; whether survival is impacted is unclear.",
"   </p>",
"   <p>",
"    The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One multi-institutional retrospective review of 81 patients who underwent reirradiation of the breast or chest wall (median reirradiation dose 48 Gy) for locally recurrent breast cancer reported an overall complete response rate of 57 percent at a median follow-up of 12 months (range 1 to 44) from the second radiation course [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/50\">",
"       50",
"      </a>",
"      ]. At reirradiation, 80 percent received standard 1.8 to 2.0 Gy daily treatments, 20 percent received twice-daily RT, 54 percent were treated with concurrent hyperthermia, and 54 percent received concurrent chemotherapy. Reirradiation was well tolerated as only four patients developed late grade 3 or 4 toxicity. Of 25 patients who had follow-up exceeding 20 months, no late grade 3 or 4 toxicities were noted. The one-year local disease-free survival rate was significantly higher for patients without gross disease at the time of reirradiation (100 versus 53 percent).",
"     </li>",
"     <li>",
"      In a German series, limited RT fields were used to treat 40 of the 67 patients who recurred in the chest wall after having received immediate postmastectomy chest wall irradiation; the majority was initially resected [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/15\">",
"       15",
"      </a>",
"      ]. Locoregional control rates were lower in patients who had received postmastectomy irradiation as compared to the group of patients without preceding irradiation whose RT fields were larger (79 versus 91 percent, respectively). However, five-year survival rates after treatment of the isolated locoregional recurrence were not worse (45 and 40 percent, respectively). Outcomes were not reported for the 27 patients who recurred after receiving immediate postmastectomy RT and who did not undergo reirradiation.",
"     </li>",
"     <li>",
"      Local control rates of approximately 70 percent at one year have been noted in other small series of patients with a previously irradiated chest wall who were treated with limited irradiation fields to only the site of recurrent disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/50,73,74\">",
"       50,73,74",
"      </a>",
"      ]. In general, treatment-related morbidity has been acceptable and limited to dry",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      moist desquamation with no evidence of soft tissue necrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, if reirradiation is undertaken, we try to limit the dose to critical structures, including the ribs, sometimes using a more superficial type of beam (eg, electrons) or twice a day irradiation (hyperfractionated RT) to reduce the significant risk of late side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthermia in the temperature range from 40 to 45&ordm;C is cytotoxic. Interest in combining heat and irradiation (thermoradiotherapy) was motivated by the observation that heat-induced and RT-induced injury could be synergistic, and the different mechanisms that underlie resistance to damage by either modality.",
"   </p>",
"   <p>",
"    Whether the addition of hyperthermia to conventional external beam RT is of clinical benefit is unknown. At least six randomized trials have compared RT with and without hyperthermia in the setting of measurable breast cancer where local therapy was indicated and surgery not feasible. Most have never been published, and the trials had a number of weaknesses, including the fact that at least two were stopped before reaching target accrual, the eligibility requirements of all of the trials varied markedly, and the primary endpoint was complete local response rather than survival.",
"   </p>",
"   <p>",
"    A meta-analysis was conducted of five of these trials, in which approximately one-half of the total 307 patients had disease outside of the treated area at the time of treatment, and three-fourths progressed outside of the field following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/75\">",
"     75",
"    </a>",
"    ]. It was concluded that the addition of hyperthermia to RT improved the complete response rate (59 versus 41 percent), but had no impact on survival (median survival was 18 months regardless of the treatment received). Substantial heterogeneity among the patient populations and the treatment parameters, and the widely varying response rates in the various studies limited the ability to determine what role, if any, was played by hyperthermia as an adjuvant to RT.",
"   </p>",
"   <p>",
"    Results from a few more contemporary but uncontrolled series are available that focus on women with recurrent breast cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most favorable report of combined hyperthermia and RT (44 to 66 Gy, median 60 Gy) after a marginal resection included 37 patients who were treated for locally recurrent breast cancer between 1997 and 2001 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/76\">",
"       76",
"      </a>",
"      ]. With a median follow-up of 28 months, three-year local control at the chest wall was 81 percent.",
"     </li>",
"     <li>",
"      Others report disappointing local control rates (approximately 40 percent at five years) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/77-80\">",
"       77-80",
"      </a>",
"      ]. In the largest of these, 85 patients with locoregionally recurrent breast cancer were treated with the combined approach (mean total RT dose 59.5 Gy) between 1981 and 2001 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/77\">",
"       77",
"      </a>",
"      ]. The total RT dose was decreased in approximately one-half (mean total dose 43 Gy) because they had received prior external beam RT. A complete response was achieved in a similar number of previously irradiated and unirradiated patients, but it was low in both groups (56 and 47 percent, respectively). It is not clear whether any patient underwent an attempt at surgical resection prior to thermoradiotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the value of combining hyperthermia with RT in patients with locally recurrent breast cancer remains uncertain, but it remains an interesting area for future research.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1494193827\">",
"    <span class=\"h3\">",
"     Treatment of the internal mammary nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the internal mammary nodes (IMNs) should be included in the RT field is controversial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision by some institutions not to treat the IMNs unless they are radiographically suspicious is based upon the very low incidence of subsequent recurrence in this area, and the potential for increased lung and cardiac morbidity with extension of the radiation fields.",
"     </li>",
"     <li>",
"      On the other hand, other institutions routinely include the IMN chain in the RT field, arguing that disease recurrence at this site can lead to direct sternal bone invasion and significant morbidity, and that RT can be delivered more safely than in the past using modern radiation planning techniques.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1494193933\">",
"    <span class=\"h2\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy (PDT) uses a photosensitizing agent that preferentially accumulates in malignant tissue; subsequent exposure of the tumor to laser light induces a phototoxic reaction and selective tumor necrosis. Promising results with PDT have been achieved in a variety of skin cancers and other malignancies as well as premalignant lesions of the upper aerodigestive tract. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\", section on 'Photodynamic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37749?source=see_link\">",
"     \"Photodynamic therapy of lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=see_link\">",
"     \"Photodynamic therapy for ablation of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical experience with PDT for locoregionally advanced breast cancer is limited. Small retrospective series demonstrate that PDT can selectively destroy locally recurrent chest wall tumors while preserving the local normal tissues and without systemic toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/81-88\">",
"     81-88",
"    </a>",
"    ]. However, technical issues such as the optimal photosensitizer dose and route of administration, as well as the proper light dose to minimize treatment-related toxicity are still being worked out. Furthermore, the impact on long-term disease control is unclear. Nevertheless, if local expertise is available, PDT represents a reasonable treatment approach, particularly after all other local treatments have been exhausted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT OF REGIONAL AXILLARY AND/OR SUPRACLAVICULAR RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like chest wall recurrences, the risk of a regional recurrence after mastectomy depends on many factors, including tumor size, the number of initially positive nodes, and whether postmastectomy RT was given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link&amp;anchor=H4#H4\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Risk factors for locoregional recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most regional recurrences present as a palpable mass detected on routine follow-up examination. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Presenting signs and symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In most series, the supraclavicular nodes are the most commonly involved site, while others note a higher rate of recurrence in the axillary nodes. This distribution may change with the increasing use of sentinel lymph node (SLN) biopsy. However, early follow-up from uncontrolled reports suggests that axillary recurrence rates are low in women with a negative SLN who do not undergo completion axillary lymph node dissection (ALND, (",
"    <a class=\"graphic graphic_table graphicRef61866 \" href=\"UTD.htm?21/9/21660\">",
"     table 3",
"    </a>",
"    )). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, patients with an isolated regional recurrence do worse than those who have an isolated chest wall recurrence. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prognostic factors'",
"    </a>",
"    above.) When only the regional nodes are involved, patients with an isolated axillary recurrence do better than those who recur in the supraclavicular nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/15,57,70,71,73,89-92\">",
"     15,57,70,71,73,89-92",
"    </a>",
"    ], largely because patients with a supraclavicular recurrence have particularly high rates of distant metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Axillary recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of an axillary recurrence is evolving in parallel with the increasing use of SLN biopsy and postmastectomy chest wall irradiation. As with an isolated chest wall recurrence, the general approach is to rule out distant metastases and whenever possible, resect the area of recurrent disease. Patients who undergo gross surgical excision have better regional control than those treated by radiation therapy (RT) alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/57,90,92\">",
"     57,90,92",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Surgical resection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In one series of 145 patients undergoing RT for a postmastectomy locoregional recurrence, most of whom underwent combined modality therapy, the five-year survival rate among those with an isolated axillary recurrence was 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who had an initially negative SLN biopsy but now have an axillary recurrence, a complete axillary lymph node dissection (levels I and II) is indicated. An attempt at resection is also indicated for those with an isolated axillary recurrence after initial ALND. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link&amp;anchor=H10450984#H10450984\">",
"     \"Management of the regional lymph nodes in breast cancer\", section on 'Extent of dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a paucity of data to guide postsurgical management of an axillary regional recurrence, and practice is variable. Multidisciplinary evaluation and management is essential. An important issue to be considered is whether RT was previously administered to the axilla, and the potential for injury to the brachial plexus and chronic lymphedema of the ipsilateral upper extremity. Lymphedema rates are higher when patients undergo both axillary RT and axillary surgery compared to either treatment alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     No prior regional RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some institutions offer postresection RT to the axilla and chest wall to women who have not previously received RT regardless of whether they recurred after SLN biopsy or ALND. At other institutions, surgery alone is favored for women who did not have an initial ALND, as long as the resection is complete. There is more consensus as to the benefit of postresection RT for patients who have an axillary recurrence after a prior ALND.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Prior RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who have had previous axillary RT, limited field reirradiation may be considered in the setting of an incompletely resected axillary regional recurrence or for local control of inoperable",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progressive local disease that is nonresponsive to systemic therapy. The decision to reirradiate limited fields should be individualized, after a thorough discussion of the risks and benefits with the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Isolated supraclavicular recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM staging classification for breast cancer considers supraclavicular disease as N3 involvement rather than a metastatic (M) site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24278?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite this, there continues to be debate as to whether patients with isolated supraclavicular relapse should be considered as having disseminated disease or locoregional disease for which aggressive treatment with curative intent is justified [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/93\">",
"     93",
"    </a>",
"    ]. Outcomes are less favorable for patients with an isolated supraclavicular as compared to axillary regional recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prognostic factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    All of the published data on treatment and outcomes among women with ipsilateral isolated supraclavicular node recurrences after either mastectomy or breast conserving therapy come from retrospective analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/94-103\">",
"     94-103",
"    </a>",
"    ]. The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest series consisted of 305 patients derived from the Danish Breast Cancer Cooperative Group Database who had an isolated supraclavicular recurrence with or without other locoregional metastases but without distant recurrence as the site of first recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/99\">",
"       99",
"      </a>",
"      ]. Patients were treated between 1977 and 2003 with either initial mastectomy or breast conserving therapy and 70 (23 percent) had prior RT. Synchronous sites of locoregional recurrence were present at the time of supraclavicular recurrence in 117 (38 percent).",
"      <br/>",
"      <br/>",
"      Locoregional treatment consisted of removal of at least the macroscopic tumor (19 percent), or curative RT (33 percent); only 10 percent had combined surgery plus RT. Overall, 78 patients (26 percent) had combined locoregional and systemic (endocrine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy) therapy, while 49 percent received systemic therapy only, and 25 percent had locoregional treatment alone.",
"      <br/>",
"      <br/>",
"      Combined locoregional and systemic therapy resulted in the highest rate of initial remission compared to either locoregional therapy alone or systemic therapy alone (67 versus 64 and 40 percent, respectively). During the entire follow-up period, 66 patients (22 percent) remained free of evidence of disease progression, whereas 138 ultimately progressed locally and 96 progressed with distant metastases. Five-year rates of progression-free and overall survival were 15 and 24 percent, respectively. In multivariate analysis, type of treatment and histologic grade of differentiation were the only independent prognostic factors, with the best outcomes in patients who received combined locoregional and systemic therapy.",
"     </li>",
"     <li>",
"      Another retrospective series included 63 women with an isolated supraclavicular nodal recurrence after primary treatment for breast cancer (predominantly mastectomy) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/98\">",
"       98",
"      </a>",
"      ]. Treatment consisted of excisional biopsy or more radical surgery in 44, RT in 25, systemic chemotherapy in 51, and hormone therapy in 42. At a median follow-up of 58 months, the five-year distant metastases-free survival rate was 15 percent. Five-year overall survival after recurrence was significantly better for women &le;40 years of age than for older women (43 and 16 percent, respectively).",
"     </li>",
"     <li>",
"      Long-term results from combined modality therapy for isolated supraclavicular recurrence in 70 patients with prior breast conserving therapy was reported by a group from M D Anderson [",
"      <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/102\">",
"       102",
"      </a>",
"      ]. All patients receiving neoadjuvant chemotherapy followed by locoregional management (total or segmental mastectomy with ALND, before or after RT), and then additional postoperative chemotherapy, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      if hormone receptor-positive. At a median followup of 11.6 years, the ten-year disease-free and overall survival rates were 32 and 31 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although they are not derived from randomized trials, taken together, these data support the view that approximately 15 to 30 percent of patients who present with an isolated supraclavicular nodal relapse will have prolonged period of disease-free survival after aggressive multimodality therapy. Thus, these patients should be approached with curative intent.",
"   </p>",
"   <p>",
"    The optimal sequence of systemic and locoregional treatment is not established. For patients who are considered candidates for systemic therapy, we prefer initial systemic therapy. At the time of restaging, if there is still no evidence of distant metastatic spread, surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy could be considered for disease control, depending on whether RT was previously administered, the magnitude of the response, the volume of residual disease, as well as the expected morbidity of both therapies. RT alone may be used if the area was not previously irradiated, surgery alone if RT was previously given, and a combination approach if there has been an incomplete response to chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SYSTEMIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35227675\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who have undergone resection of a locoregional recurrence, the use of chemotherapy following resection has been controversial due to the presence of only low quality evidence that specifically addressed this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/104\">",
"     104",
"    </a>",
"    ]. However, the results of a randomized trial which were presented at the 2012 San Antonio Breast Cancer Conference suggests there is a benefit to post-excision chemotherapy, particularly among women with estrogen receptor (ER)-negative disease.",
"   </p>",
"   <p>",
"    In the Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR) trial, 162 patients who underwent surgical resection of locally recurrent breast cancer were randomly assigned to post-excision chemotherapy treatment (with the regimen determined by the patient&rsquo;s treating oncologist) or to no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/105\">",
"     105",
"    </a>",
"    ]. All patients were advised to undergo RT although RT was mandatory for women with microscopically involved surgical margins. Of the patients enrolled, more women in the treatment group were chemotherapy naive compared to the group randomized to no treatment (42 versus 32 percent, respectively) and premenopausal at the time of recurrence (24 versus 18 percent). A similar proportion of women underwent RT following resection of their local recurrence (44 versus 39 percent). Compared to no treatment, post-resection chemotherapy resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant improvement in the five-year overall survival rate compared to those who did not receive chemotherapy (OS, 88 versus 76 percent, respectively; hazard ratio [HR] 0.41, 95% CI 0.19-0.89)",
"     </li>",
"     <li>",
"      A significant improvement in the five-year disease free survival rate (DFS, 69 versus 57 percent, respectively; HR 0.59, 95% CI 0.35-0.99)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A larger benefit in survival with the administration of adjuvant chemotherapy was reported for women with ER-negative breast cancer compared to those with ER-positive disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among women with ER-negative breast cancer treated with chemotherapy versus no chemotherapy, five-year DFS was 67 versus 35 percent, respectively (HR 0.32, 95% CI 0.14-0.73); five-year OS was 79 versus 69 percent (HR 0.43, 95% CI 0.15-1.24).",
"     </li>",
"     <li>",
"      Among women with ER-positive breast cancer, five-year DFS was 70 versus 69 percent (HR 0.94, 95% CI 0.47-1.89); five-year OS was 94 versus 80 percent (HR 0.40, 95% CI 0.12-1.28).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While presented in abstract form only, these data support the use of chemotherapy in women with breast cancer following resection for locoregional recurrence. However, whether the benefits of treatment are similar based on the location of recurrence (eg, chest wall versus regional nodal recurrence), prior treatment with chemotherapy or RT, or breast cancer subtype (eg, triple-negative, HER-2 positive, or hormone receptor-positive) is not clear.",
"   </p>",
"   <p>",
"    Based on these data, women with ER-negative disease (in whom endocrine therapy is not an option) should receive adjuvant chemotherapy following resection of a locoregional recurrence. We await publication of the final results prior to determining the role of chemotherapy following resection for women with ER-positive disease in whom endocrine therapy is the primary treatment (see",
"    <a class=\"local\" href=\"#H35227682\">",
"     'Endocrine therapy'",
"    </a>",
"    below). All women with HER2-positive disease should receive a HER2-directed agent.",
"   </p>",
"   <p>",
"    As in the adjuvant setting (and in the CALOR trial), we prefer to administer chemotherapy prior to initiation of RT. The selection of treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35227682\">",
"    <span class=\"h2\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with hormone receptor-positive breast cancer should be treated with endocrine therapy, regardless of whether adjuvant chemotherapy was administered. Although there are limited data to support the benefit of treatment in this clinical setting, treatment is based on the benefits of endocrine therapy in the adjuvant setting and as treatment for metastatic breast cancer.",
"   </p>",
"   <p>",
"    The only randomized trial evaluating the benefit of endocrine therapy in this setting assigned 167 women with hormone receptor-positive or hormone receptor-unknown locally recurrent breast cancer (all of whom underwent resection of disease) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or observation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/45/30426/abstract/106\">",
"     106",
"    </a>",
"    ]. With a median follow-up of 11 years, the median disease free survival (DFS) following the initial locoregional recurrence was longer with tamoxifen compared to observation (6.5 versus 2.7 years, respectively, p=0.053). This translated into a significant improvement in the five-year DFS rate favoring tamoxifen (61 versus 33 percent, p=0.006). However, there was no difference in median overall survival (OS) in the overall population (11.5 versus 11.2 years, respectively). &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"     \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Is there a role for neoadjuvant treatment?",
"    </span>",
"    &nbsp;&mdash;&nbsp;While in many cases systemic therapy will be considered following locoregional therapy, it represents appropriate initial therapy in certain situations. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial trial of systemic therapy in patients who have an apparently isolated supraclavicular nodal recurrence can help to identify those patients with early distant dissemination, in whom locoregional therapy might not be beneficial. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Isolated supraclavicular recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with sizable chest wall recurrence that would require a large resection, a response to neoadjuvant therapy may simplify the extent of surgery (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgical resection'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Diagnosis and pretreatment evaluation",
"    </span>",
"   </p>",
"   <p>",
"    Between 10 and 15 percent of patients will develop a locoregional recurrence within 10 years of undergoing mastectomy for operable breast cancer. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A postmastectomy local recurrence is usually detected clinically as a mass or multiple nodules in the chest wall or overlying skin; uncommonly, an isolated supraclavicular or axillary mass is the only sign. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Diagnosis and Pretreatment evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Between 50 and 70 percent of locoregional recurrences following mastectomy are isolated to the chest wall; 30 to 40 percent have local plus regional recurrence in the supraclavicular, axillary, or internal mammary nodes. One-third of cases have synchronous distant metastatic disease at the time of diagnosis. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Incidence and characteristics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnostic evaluation of a patient with a suspected postmastectomy locoregional recurrence should include a full staging workup to exclude the presence of distant metastases. Biopsy is warranted to confirm the disease recurrence and to test for expression of hormone receptors and HER2. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Staging workup'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with a locoregional recurrence after mastectomy is complex and usually requires multidisciplinary assessment and planning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Isolated chest wall recurrence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend wide local excision of all gross disease, whenever possible, for solitary or multiple nodules that are amenable to resection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgical resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with a large or categorically unresectable chest wall recurrence, we suggest initial chemotherapy rather than locoregional treatment, if the patient is a candidate for systemic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Induction therapy can facilitate successful locoregional treatment, and patients can be observed for early evidence of distant metastases. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Is there a role for neoadjuvant treatment?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient did not previously have a complete axillary lymph node dissection (ALND), and there is clinical evidence of axillary regional disease, we suggest ALND rather than SLN biopsy as long as there is no evidence of distant metastases (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If the patient had a complete ALND initially and has no clinical evidence of regional disease, we suggest not reexploring the axilla (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Management of the axilla'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Opinion differs as to the need for axillary restaging in a patient who had a prior ALND and now presents with a chest wall recurrence and no clinical evidence of regional axillary disease. The decision whether to perform a re-do ALND in this setting should take into account the extent of the previous axillary surgery or radiation therapy, the initial disease stage and likelihood of distant metastases, the pathology of the recurrence (in situ versus invasive) and the impact that the identification of regional disease will have on adjuvant therapy decisions, if any. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Management of the axilla'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have not previously undergone chest wall irradiation, we suggest postresection radiation therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The entire chest wall and draining lymph node areas should be treated, even if the recurrence is localized to a small area of the chest wall. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Radiation therapy'",
"      </a>",
"      above.) Some institutions consider surgery alone to be an acceptable option if the recurrence pattern is a single nodule, the relapse-free interval is longer than two years, and the resection margins are completely negative. However, this is not a standard approach, and this decision should be made on a case by case basis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of an isolated chest wall recurrence'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients who previously had immediate postmastectomy RT, we suggest limited field reirradiation only for those patients who have inoperable or incompletely resected recurrent disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management of previously irradiated women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Axillary regional recurrence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with an isolated axillary recurrence or axillary plus chest wall recurrence, management depends on whether ALND was previously undertaken, and whether the patient previously had regional irradiation. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Axillary recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who had an initially negative SLN biopsy but now have an axillary recurrence, we recommend complete axillary lymph node dissection (levels I and II) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients who recur after a prior ALND, we recommend axillary exploration and an attempt to completely resect all disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The benefit of postresection RT in such patients is unclear, and opinion differs as to the optimal approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Some institutions offer postresection RT to the axilla and chest wall in women who have not previously received RT, regardless of whether they recurred after SLN biopsy or ALND. For previously irradiated patients, limited field reirradiation is considered only in the setting of an incompletely resected axillary regional recurrence or for local control of inoperable",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progressive local disease that is nonresponsive to systemic therapy. The decision to reirradiate limited fields should be individualized, after a thorough discussion of the risks and benefits with the patient.",
"     </li>",
"     <li>",
"      At other institutions, surgery alone is favored for women with an isolated axillary recurrence who did not have an initial ALND, as long as the resection is complete. There is more consensus as to the benefit of postresection RT for patients who have an axillary recurrence after a prior ALND.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Supraclavicular regional recurrence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with an isolated supraclavicular recurrence without distant metastases should be approached with curative intent. For patients who are considered candidates for systemic therapy, we suggest initial systemic therapy rather than locoregional therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). At the time of restaging, if there is still no evidence of distant metastatic spread, surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy can be offered for disease control, depending on the magnitude of the response, the volume of residual disease, as well as the expected morbidity of both therapies. RT alone may be used if the area was not previously irradiated, surgery alone if RT was previously given, and a combination approach if there has been an incomplete response to chemotherapy. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Isolated supraclavicular recurrence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Role of adjuvant systemic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with ER-negative disease who have undergone resection for locoregionally recurrent disease, we recommend post-excision chemotherapy rather than observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H35227675\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with ER-positive breast cancer who have undergone resection for locoregionally recurrent disease, we recommend endocrine therapy following excision rather than observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The benefit of additional systemic chemotherapy following resection is not clear. (See",
"      <a class=\"local\" href=\"#H35227682\">",
"       'Endocrine therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35227675\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with HER2-positive breast cancer, we recommend concomitant administration of a HER2-directed agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H35227675\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As in the adjuvant setting, we prefer to administer chemotherapy prior to RT (if indicated) following surgery.",
"     </li>",
"     <li>",
"      In some circumstances (eg, an apparently isolated supraclavicular recurrence, a large or initially unresectable chest wall recurrence), we suggest neoadjuvant systemic therapy rather than upfront locoregional therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Is there a role for neoadjuvant treatment?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/1\">",
"      van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000; 92:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/2\">",
"      Jacobson JA, Danforth DN, Cowan KH, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995; 332:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/3\">",
"      Arriagada R, L&ecirc; MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 1996; 14:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/4\">",
"      Stefanik D, Goldberg R, Byrne P, et al. Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1985; 3:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/5\">",
"      Schmoor C, Sauerbrei W, Bastert G, Schumacher M. Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol 2000; 18:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/6\">",
"      Buchanan CL, Dorn PL, Fey J, et al. Locoregional recurrence after mastectomy: incidence and outcomes. J Am Coll Surg 2006; 203:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/7\">",
"      Jatoi I, Tsimelzon A, Weiss H, et al. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 2005; 89:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/8\">",
"      van Tienhoven G, Voogd AC, Peterse JL, et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer 1999; 35:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/9\">",
"      Francis M, Cakir B, Ung O, et al. Prognosis after breast recurrence following conservative surgery and radiotherapy in patients with node-negative breast cancer. Br J Surg 1999; 86:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/10\">",
"      Dalberg K, Mattsson A, Sandelin K, Rutqvist LE. Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer. Breast Cancer Res Treat 1998; 49:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/11\">",
"      Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/12\">",
"      Freedman GM, Fowble BL. Local recurrence after mastectomy or breast-conserving surgery and radiation. Oncology (Williston Park) 2000; 14:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/13\">",
"      Pisansky TM, Ingle JN, Schaid DJ, et al. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. Cancer 1993; 72:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/14\">",
"      Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/15\">",
"      Willner J, Kiricuta IC, K&ouml;lbl O. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. Int J Radiat Oncol Biol Phys 1997; 37:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/16\">",
"      Ballo MT, Strom EA, Prost H, et al. Local-regional control of recurrent breast carcinoma after mastectomy: does hyperfractionated accelerated radiotherapy improve local control? Int J Radiat Oncol Biol Phys 1999; 44:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/17\">",
"      Haylock BJ, Coppin CM, Jackson J, et al. Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy. Int J Radiat Oncol Biol Phys 2000; 46:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/18\">",
"      Schwaibold F, Fowble BL, Solin LJ, et al. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 1991; 21:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/19\">",
"      Hsi RA, Antell A, Schultz DJ, Solin LJ. Radiation therapy for chest wall recurrence of breast cancer after mastectomy in a favorable subgroup of patients. Int J Radiat Oncol Biol Phys 1998; 42:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/20\">",
"      Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 2000; 18:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/21\">",
"      Nielsen HM, Overgaard M, Grau C, et al. Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82 b&amp;c randomization trials. Radiother Oncol 2006; 79:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/22\">",
"      Cheng SH, Horng CF, Clarke JL, et al. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. Int J Radiat Oncol Biol Phys 2006; 64:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/23\">",
"      Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/24\">",
"      Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/25\">",
"      Harris JR, Halpin-Murphy P, McNeese M, et al. Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44:989.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/27\">",
"      Truong PT, Olivotto IA, Whelan TJ, et al. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ 2004; 170:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/28\">",
"      Kuo SH, Huang CS, Kuo WH, et al. Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence. Int J Radiat Oncol Biol Phys 2008; 72:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/29\">",
"      Leibman AJ, Styblo TM, Bostwick J 3rd. Mammography of the postreconstruction breast. Plast Reconstr Surg 1997; 99:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/30\">",
"      Loyer EM, Kroll SS, David CL, et al. Mammographic and CT findings after breast reconstruction with a rectus abdominis musculocutaneous flap. AJR Am J Roentgenol 1991; 156:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/31\">",
"      Eidelman Y, Liebling RW, Buchbinder S, et al. Mammography in the evaluation of masses in breasts reconstructed with TRAM flaps. Ann Plast Surg 1998; 41:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/32\">",
"      Kim SM, Park JM. Mammographic and ultrasonographic features after autogenous myocutaneous flap reconstruction mammoplasty. J Ultrasound Med 2004; 23:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/33\">",
"      Devon RK, Rosen MA, Mies C, Orel SG. Breast reconstruction with a transverse rectus abdominis myocutaneous flap: spectrum of normal and abnormal MR imaging findings. Radiographics 2004; 24:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/34\">",
"      Helvie MA, Bailey JE, Roubidoux MA, et al. Mammographic screening of TRAM flap breast reconstructions for detection of nonpalpable recurrent cancer. Radiology 2002; 224:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/35\">",
"      Helvie MA, Wilson TE, Roubidoux MA, et al. Mammographic appearance of recurrent breast carcinoma in six patients with TRAM flap breast reconstructions. Radiology 1998; 209:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/36\">",
"      Edeiken BS, Fornage BD, Bedi DG, et al. Recurrence in autogenous myocutaneous flap reconstruction after mastectomy for primary breast cancer: US diagnosis. Radiology 2003; 227:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/37\">",
"      Salas AP, Helvie MA, Wilkins EG, et al. Is mammography useful in screening for local recurrences in patients with TRAM flap breast reconstruction after mastectomy for multifocal DCIS? Ann Surg Oncol 1998; 5:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/38\">",
"      McCarthy CM, Pusic AL, Sclafani L, et al. Breast cancer recurrence following prosthetic, postmastectomy reconstruction: incidence, detection, and treatment. Plast Reconstr Surg 2008; 121:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/39\">",
"      Barnsley GP, Grunfeld E, Coyle D, Paszat L. Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review. Plast Reconstr Surg 2007; 120:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/40\">",
"      Scatarige JC, Fishman EK, Zinreich ES, et al. Internal mammary lymphadenopathy in breast carcinoma: CT appraisal of anatomic distribution. Radiology 1988; 167:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/41\">",
"      Lindfors KK, Meyer JE, Busse PM, et al. CT evaluation of local and regional breast cancer recurrence. AJR Am J Roentgenol 1985; 145:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/42\">",
"      Rosenman J, Churchill CA, Mauro MA, et al. The role of computed tomography in the evaluation of post-mastectomy locally recurrent breast cancer. Int J Radiat Oncol Biol Phys 1988; 14:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/43\">",
"      Lingawi SS, Bilbey JH, Munk PL, et al. MR imaging of brachial plexopathy in breast cancer patients without palpable recurrence. Skeletal Radiol 1999; 28:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/44\">",
"      Radan L, Ben-Haim S, Bar-Shalom R, et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006; 107:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/45\">",
"      Eubank WB, Mankoff D, Bhattacharya M, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004; 183:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/46\">",
"      Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003; 38:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/47\">",
"      Eubank WB, Mankoff DA, Takasugi J, et al. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001; 19:3516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/48\">",
"      Bender H, Kirst J, Palmedo H, et al. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997; 17:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/49\">",
"      Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005; 90:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/50\">",
"      Wahl AO, Rademaker A, Kiel KD, et al. Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. Int J Radiat Oncol Biol Phys 2008; 70:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/51\">",
"      Eubank WB. Diagnosis of recurrent and metastatic disease using f-18 fluorodeoxyglucose-positron emission tomography in breast cancer. Radiol Clin North Am 2007; 45:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/52\">",
"      Aberizk WJ, Silver B, Henderson IC, et al. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 1986; 58:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/53\">",
"      Borner M, Bacchi M, Goldhirsch A, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 1994; 12:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/54\">",
"      Halverson KJ, Perez CA, Kuske RR, et al. Survival following locoregional recurrence of breast cancer: univariate and multivariate analysis. Int J Radiat Oncol Biol Phys 1992; 23:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/55\">",
"      Andry G, Suciu S, Vico P, et al. Locoregional recurrences after 649 modified radical mastectomies: incidence and significance. Eur J Surg Oncol 1989; 15:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/56\">",
"      Chagpar A, Kuerer HM, Hunt KK, et al. Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: implications for post-mastectomy radiation therapy. Int J Radiat Oncol Biol Phys 2003; 57:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/57\">",
"      Halverson KJ, Perez CA, Kuske RR, et al. Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. Int J Radiat Oncol Biol Phys 1990; 19:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/58\">",
"      Faneyte IF, Rutgers EJ, Zoetmulder FA. Chest wall resection in the treatment of locally recurrent breast carcinoma: indications and outcome for 44 patients. Cancer 1997; 80:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/59\">",
"      Pfannschmidt J, Geisb&uuml;sch P, Muley T, et al. Surgical resection of secondary chest wall tumors. Thorac Cardiovasc Surg 2005; 53:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/60\">",
"      Kroll SS, Schusterman MA, Larson DL, Fender A. Long-term survival after chest-wall reconstruction with musculocutaneous flaps. Plast Reconstr Surg 1990; 86:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/61\">",
"      Beck TM, Hart NE, Woodard DA, Smith CE. Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients. J Clin Oncol 1983; 1:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/62\">",
"      Salvadori B, Rovini D, Squicciarini P, et al. Surgery for local recurrences following deficient radical mastectomy for breast cancer: a selected series of 39 cases. Eur J Surg Oncol 1992; 18:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/63\">",
"      McCormack PM, Bains MS, Burt ME, et al. Local recurrent mammary carcinoma failing multimodality therapy. A solution. Arch Surg 1989; 124:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/64\">",
"      Toi M, Tanaka S, Bando M, et al. Outcome of surgical resection for chest wall recurrence in breast cancer patients. J Surg Oncol 1997; 64:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/65\">",
"      Flook D, Webster DJ, Hughes LE, Mansel RW. Salvage surgery for advanced local recurrence of breast cancer. Br J Surg 1989; 76:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/66\">",
"      Dahlstr&oslash;m KK, Andersson AP, Andersen M, Krag C. Wide local excision of recurrent breast cancer in the thoracic wall. Cancer 1993; 72:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/67\">",
"      Miyauchi K, Koyama H, Noguchi S, et al. Surgical treatment for chest wall recurrence of breast cancer. Eur J Cancer 1992; 28A:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/68\">",
"      Friedel G, Kuipers T, Dippon J, et al. Full-thickness resection with myocutaneous flap reconstruction for locally recurrent breast cancer. Ann Thorac Surg 2008; 85:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/69\">",
"      Karam A, Stempel M, Cody HS 3rd, Port ER. Reoperative sentinel lymph node biopsy after previous mastectomy. J Am Coll Surg 2008; 207:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/70\">",
"      Deutsch M, Parsons JA, Mittal BB. Radiation therapy for local-regional recurrent breast carcinoma. Int J Radiat Oncol Biol Phys 1986; 12:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/71\">",
"      Mendenhall NP, Devine JW, Mendenhall WM, et al. Isolated local-regional recurrence following mastectomy for adenocarcinoma of the breast treated with radiation therapy alone or combined with surgery and/or chemotherapy. Radiother Oncol 1988; 12:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/72\">",
"      Haffty BG, Hauser A, Choi DH, et al. Molecular markers for prognosis after isolated postmastectomy chest wall recurrence. Cancer 2004; 100:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/73\">",
"      Chen KK, Montague ED, Oswald MJ. Results of irradiation in the treatment of locoregional breast cancer recurrence. Cancer 1985; 56:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/74\">",
"      Elkort RJ, Kelly W, Mozden PJ, Feldman MI. A combined treatment program for the management of locally recurrent breast cancer following chest wall irradiation. Cancer 1980; 46:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/75\">",
"      Vernon CC, Hand JW, Field SB, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996; 35:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/76\">",
"      Welz S, Hehr T, Lamprecht U, et al. Thermoradiotherapy of the chest wall in locally advanced or recurrent breast cancer with marginal resection. Int J Hyperthermia 2005; 21:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/77\">",
"      Li G, Mitsumori M, Ogura M, et al. Local hyperthermia combined with external irradiation for regional recurrent breast carcinoma. Int J Clin Oncol 2004; 9:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/78\">",
"      Lee HK, Antell AG, Perez CA, et al. Superficial hyperthermia and irradiation for recurrent breast carcinoma of the chest wall: prognostic factors in 196 tumors. Int J Radiat Oncol Biol Phys 1998; 40:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/79\">",
"      Kapp DS, Cox RS. Thermal treatment parameters are most predictive of outcome in patients with single tumor nodules per treatment field in recurrent adenocarcinoma of the breast. Int J Radiat Oncol Biol Phys 1995; 33:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/80\">",
"      Feyerabend T, Wiedemann GJ, J&auml;ger B, et al. Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease. Int J Radiat Oncol Biol Phys 2001; 49:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/81\">",
"      Schuh M, Nseyo UO, Potter WR, et al. Photodynamic therapy for palliation of locally recurrent breast carcinoma. J Clin Oncol 1987; 5:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/82\">",
"      Sperduto PW, DeLaney TF, Thomas G, et al. Photodynamic therapy for chest wall recurrence in breast cancer. Int J Radiat Oncol Biol Phys 1991; 21:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/83\">",
"      Khan SA, Dougherty TJ, Mang TS. An evaluation of photodynamic therapy in the management of cutaneous metastases of breast cancer. Eur J Cancer 1993; 29A:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/84\">",
"      Mang TS, Allison R, Hewson G, et al. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J Sci Am 1998; 4:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/85\">",
"      Wyss P, Schwarz V, Dobler-Girdziunaite D, et al. Photodynamic therapy of locoregional breast cancer recurrences using a chlorin-type photosensitizer. Int J Cancer 2001; 93:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/86\">",
"      Lapes M, Petera J, Jirsa M. Photodynamic therapy of cutaneous metastases of breast cancer after local application of meso-tetra-(para-sulphophenyl)-porphin (TPPS4). J Photochem Photobiol B 1996; 36:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/87\">",
"      Koren H, Alth G, Schenk GM, Jindra RH. Photodynamic therapy--an alternative pathway in the treatment of recurrent breast cancer. Int J Radiat Oncol Biol Phys 1994; 28:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/88\">",
"      Allison R, Mang T, Hewson G, et al. Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality. Cancer 2001; 91:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/89\">",
"      Halverson KJ, Perez CA, Kuske RR, et al. Locoregional recurrence of breast cancer: a retrospective comparison of irradiation alone versus irradiation and systemic therapy. Am J Clin Oncol 1992; 15:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/90\">",
"      Recht A, Pierce SM, Abner A, et al. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol 1991; 9:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/91\">",
"      Galper S, Blood E, Gelman R, et al. Prognosis after isolated axillary nodal recurrence following conservative surgery and radiotherapy for early-stage bareast carcinoma (abstract). Int J Radiat Oncol Biol Phys 2002; 54(2 suppl):56s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/92\">",
"      Fowble B, Solin LJ, Schultz DJ, Goodman RL. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys 1989; 17:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/93\">",
"      Jagsi R. Breast cancer in the supraclavicular region: is the horse out of the barn? Breast Cancer Res Treat 2011; 125:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/94\">",
"      Pergolizzi S, Adamo V, Russi E, et al. Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. Int J Radiat Oncol Biol Phys 2006; 65:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/95\">",
"      van der Sangen MJ, Coebergh JW, Roumen RM, et al. Detection, treatment, and outcome of isolated supraclavicular recurrence in 42 patients with invasive breast carcinoma. Cancer 2003; 98:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/96\">",
"      Ampil FL, Caldito G, Li BD, Burton GV. Supraclavicular nodal relapse of breast cancer: prevalence, palliation, and prognosis. Eur J Gynaecol Oncol 2003; 24:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/97\">",
"      Kiricuta IC, Willner J, K&ouml;lbl O, Bohndorf W. The prognostic significance of the supraclavicular lymph node metastases in breast cancer patients. Int J Radiat Oncol Biol Phys 1994; 28:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/98\">",
"      Chen SC, Chang HK, Lin YC, et al. Prognosis of breast cancer after supraclavicular lymph node metastasis: not a distant metastasis. Ann Surg Oncol 2006; 13:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/99\">",
"      Pedersen AN, M&oslash;ller S, Steffensen KD, et al. Supraclavicular recurrence after early breast cancer: a curable condition? Breast Cancer Res Treat 2011; 125:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/100\">",
"      Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 2006; 24:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/101\">",
"      Harris EE, Hwang WT, Seyednejad F, Solin LJ. Prognosis after regional lymph node recurrence in patients with stage I-II breast carcinoma treated with breast conservation therapy. Cancer 2003; 98:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/102\">",
"      Brito RA, Valero V, Buzdar AU, et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 2001; 19:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/103\">",
"      Reddy JP, Levy L, Oh JL, et al. Long-term outcomes in patients with isolated supraclavicular nodal recurrence after mastectomy and doxorubicin-based chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys 2011; 80:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/104\">",
"      Olson CE, Ansfield FJ, Richards MJ, et al. Review of local soft tissue recurrence of breast cancer irradiated with and without actinomycin-D. Cancer 1977; 39:1981.",
"     </a>",
"    </li>",
"    <li>",
"     Aebi S, Gelber S, L&aacute;ng I, et al. Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: the CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). 2012 CTRC-AACR San Antonio Breast Cancer Symposium; Abstract S3-2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/45/30426/abstract/106\">",
"      Waeber M, Castiglione-Gertsch M, Dietrich D, et al. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 2003; 14:1215.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 772 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-71903B288C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30426=[""].join("\n");
var outline_f29_45_30426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Distribution and time course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Impact of postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS AND PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Presenting signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Findings on imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Staging workup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      GENERAL TREATMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT OF AN ISOLATED CHEST WALL RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgical resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Management of the axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1494193792\">",
"      - No prior RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Management of previously irradiated women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1494193827\">",
"      - Treatment of the internal mammary nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1494193933\">",
"      Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT OF REGIONAL AXILLARY AND/OR SUPRACLAVICULAR RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Axillary recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - No prior regional RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Prior RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Isolated supraclavicular recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SYSTEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35227675\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35227682\">",
"      Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Is there a role for neoadjuvant treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Diagnosis and pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Isolated chest wall recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Axillary regional recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Supraclavicular regional recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Role of adjuvant systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/772\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/772|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/19/39227\" title=\"table 1\">",
"      BIRADS mammography categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/40/22157\" title=\"table 2\">",
"      RT postmastectomy local recur",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/9/21660\" title=\"table 3\">",
"      Axillary recur neg SLN biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=related_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34650?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35831?source=related_link\">",
"      Metastatic breast cancer: Local treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=related_link\">",
"      Photodynamic therapy for ablation of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37749?source=related_link\">",
"      Photodynamic therapy of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=related_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24278?source=related_link\">",
"      Tumor node metastasis (TNM) staging classification for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_45_30427="Causes of NPE";
var content_f29_45_30427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of neurogenic pulmonary edema",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epileptic seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minor causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guillain-Barr&eacute; syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sclerosis with medullary involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonhemorrhagic strokes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trigeminal nerve block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bulbar poliomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vertebral artery ligation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ruptured spinal arteriovenous malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Air embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electroconvulsive therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Induction of general anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colloid cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocephalus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reye's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral meningoencephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical spinal cord injury",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30427=[""].join("\n");
var outline_f29_45_30427=null;
var title_f29_45_30428="Rx HACEK PVE";
var content_f29_45_30428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested regimens for therapy of prosthetic valve endocarditis due to HACEK* microorganism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       American Heart Association",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       European Society of Cardiology&sect;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Adult (for patients with normal renal function)",
"      </td>",
"      <td class=\"subtitle2\">",
"       Pediatric (not to exceed dose of normal adult)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       <p>",
"        <strong>",
"         One of the following:",
"        </strong>",
"       </p>",
"       <p>",
"        Ceftriaxone&bull; 2 g per 24 h IV or IM in 1 dose for 6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ampicillin-sulbactam 12 g per 24 h IV in 4 equally divided doses for 6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ciprofloxacin&loz; 1000 mg per 24 h PO or 800 mg per 24 h IV in 2 equally divided doses for 6 wks",
"       </p>",
"      </td>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       <p>",
"        <strong>",
"         One of the following:",
"        </strong>",
"       </p>",
"       <p>",
"        Ceftriaxone&bull; 100 mg/kg per 24 h IV or IM in 1 dose for 6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ampicillin-sulbactam 300 mg/kg per 24 h IV in 4 or 6 equally divided doses for 6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ciprofloxacin&loz; 20-30 mg/kg per 24 h IV or PO in 2 equally divided doses for 6 wks",
"       </p>",
"      </td>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       <p>",
"        <strong>",
"         One of the following:",
"        </strong>",
"       </p>",
"       <p>",
"        Ceftriaxone&bull; 2 g per 24 h IV or IM in 1 dose for 6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Combination therapy with: ampicillin&Delta; 12 g per 24 h IV in 4 equally divided doses for 6 wks",
"        <strong>",
"         PLUS",
"        </strong>",
"        gentamicin&Delta; 3 mg/kg per 24 h IV or IM divided in 2 or 3 doses for 6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ciprofloxacin&loz; 1000 mg per 24 h PO or 800 mg per 24 h IV in 2 equally divided doses for 6 wks",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Haemophilus parainfluenzae, Aggregatibacter aphrophilus (formerly Haemophilus aphrophilus), Aggregatibacter actinomycetemcomitans (formerly Actinobacillus actinomycetemcomitans), Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae.",
"     <br>",
"      &bull; Cefotaxime or another third- or fourth-generation cephalosporin may be substituted.",
"      <br>",
"       &Delta; If organisms are proven to not produce beta-lactamase.",
"       <br>",
"        &loz; Fluoroquinolone therapy recommended only for patients unable to tolerate cephalosporin and ampicillin therapy; levofloxacin, or moxifloxacin may be substituted. Use with caution in patients &lt; 18 years old.",
"        <br>",
"         &sect; Duration of treatment extrapolated from American Heart Association recommendations.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Circulation 2005;111:3167; Eur Heart J 2009;30:2369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30428=[""].join("\n");
var outline_f29_45_30428=null;
var title_f29_45_30429="Antibiotic lock solutions without anticoagulant";
var content_f29_45_30429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Final concentrations of antibiotic lock solutions without anticoagulant for treatment of catheter-related bloodstream infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antibiotic and concentration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum dwell time",
"        <br/>",
"        (duration of stability)",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;References",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin 1 mg/mL",
"       </td>",
"       <td>",
"        48 hours",
"       </td>",
"       <td>",
"        &nbsp;[1]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aztreonam 83.3 mg/mL",
"       </td>",
"       <td>",
"        12 hours",
"       </td>",
"       <td>",
"        &nbsp;[2]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefepime 1 mg/mL",
"       </td>",
"       <td>",
"        48 hours",
"       </td>",
"       <td>",
"        &nbsp;[1]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefepime 10 mg/mL",
"       </td>",
"       <td>",
"        48 hours",
"       </td>",
"       <td>",
"        &nbsp;[1]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftazidime 5 mg/mL",
"       </td>",
"       <td>",
"        48 hours",
"       </td>",
"       <td>",
"        &nbsp;[1]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftriaxone 83.3 mg/mL",
"       </td>",
"       <td>",
"        12 hours",
"       </td>",
"       <td>",
"        &nbsp;[2]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin 5 mg/mL",
"       </td>",
"       <td>",
"        48 hours",
"       </td>",
"       <td>",
"        &nbsp;[3]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daptomycin 5 mg/mL*",
"       </td>",
"       <td>",
"        72 hours",
"       </td>",
"       <td>",
"        &nbsp;[4]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gentamicin 13.3 mg/mL",
"       </td>",
"       <td>",
"        12 hours",
"       </td>",
"       <td>",
"        &nbsp;[2]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minocycline 2 mg/mL",
"       </td>",
"       <td>",
"        4 hours",
"       </td>",
"       <td>",
"        &nbsp;[5]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nafcillin 83.3 mg/mL",
"       </td>",
"       <td>",
"        12 hours",
"       </td>",
"       <td>",
"        &nbsp;[2]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampicin 5 mg/mL",
"       </td>",
"       <td>",
"        48 hours",
"       </td>",
"       <td>",
"        &nbsp;[3]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teicoplanin 10 mg/mL",
"       </td>",
"       <td>",
"        48 hours",
"       </td>",
"       <td>",
"        &nbsp;[3]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tigecycline 2 mg/mL",
"       </td>",
"       <td>",
"        4 hours",
"       </td>",
"       <td>",
"        &nbsp;[5]",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Vancomycin 5 mg/mL",
"       </td>",
"       <td>",
"        72 hours",
"       </td>",
"       <td>",
"        &nbsp;[4]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Combinations",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Daptomycin 2 mg/mL* and rifampin 2 mg/mL",
"       </td>",
"       <td>",
"        4 hours",
"       </td>",
"       <td>",
"        &nbsp;[5]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Linezolid 2 mg/mL and rifampin 2 mg/mL",
"       </td>",
"       <td>",
"        4 hours",
"       </td>",
"       <td>",
"        &nbsp;[5]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Minocycline 2 mg/mL and rifampin 2 mg/mL",
"       </td>",
"       <td>",
"        4 hours",
"       </td>",
"       <td>",
"        &nbsp;[5]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tigecycline 2 mg/mL and rifampin 2 mg/mL",
"       </td>",
"       <td>",
"        4 hours",
"       </td>",
"       <td>",
"        &nbsp;[5]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vancomycin 2 mg/mL and rifampin 2 mg/mL",
"       </td>",
"       <td>",
"        4 hours",
"       </td>",
"       <td>",
"        &nbsp;[5]",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table lists&nbsp;clinically useful antibiotic solutions that do not contain an anticoagulant and can be used in patients who have a contraindication to heparin. Otherwise, solutions containing both an antibiotic and an anticoagulant are&nbsp;preferred. The doses included have optimal stability and/or in vitro data to support their use. Antibiotic lock solutions for the treatment of catheter-related bloodstream infections should be used in conjunction with systemic antibiotic therapy. Antibiotic concentrations may decrease to subtherapeutic levels in the distal lumen of the catheter when dwell times exceed 48 hours, but for hemodialysis catheters, it is reasonable to allow the solution to dwell during the interval between sessions, up to 72 hours. If the line must be accessed for alternate use during the dwell time, the lock solution should be removed and later replaced anew.",
"    <div class=\"footnotes\">",
"     * Daptomycin solution contained 50 mg/L of calcium, which is necessary for antibiotic activity.",
"     <br>",
"      <em>",
"       1. Lee MY, Ko KS, Song JH, Peck KR. In vitro effectiveness of the antibiotic lock technique (ALT) for the treatment of catheter-related infections by Pseudomonas aeruginosa and Klebsiella pneumoniae. J Antimicrob Chemother 2007; 60:782.",
"       <br>",
"        2. Andris DA, Krzywda EA, Edmiston CE, et al. Elimination of intraluminal colonization by antibiotic lock in silicone vascular catheters. Nutrition 1998; 14:427.",
"        <br>",
"         3. Lee JY, Ko KS, Peck KR, et al. In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci. J Antimicrob Chemother 2006; 57:1110.",
"         <br>",
"          4. LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant 2007; 22:2239.",
"          <br>",
"           5. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51:1656.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </em>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30429=[""].join("\n");
var outline_f29_45_30429=null;
var title_f29_45_30430="Course of acute B19 infection";
var content_f29_45_30430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 611px\">",
"   <div class=\"ttl\">",
"    Course of parvovirus B19 infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 591px; height: 314px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the clinical course and laboratory abnormalities in normal hosts with parvovirus B19 infection. As expected for a virus that infects red cell precursors, a transient reticulocytopenia and slight drop in hemoglobin level develop during the viremic stage of infection; platelets and leukocytes (not shown) also fall during this period. Once the host mounts an immune response beginning 10 to 14 days after the infection, the viremia resolves and reticulocytes return. Note the biphasic timing of symptoms, during the peak viremia and again after the viremia has cleared. Rash, arthritis, and other symptoms typically associated with B19 occur during the second period.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30430=[""].join("\n");
var outline_f29_45_30430=null;
var title_f29_45_30431="Caustic esophageal stricture";
var content_f29_45_30431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal stricture after caustic ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 214px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel shows an esophageal stricture six weeks after lye ingestion. A gastrostomy with retrograde string placement was performed with multiple dilatations by string bougie. The patient was able to eat normally for two to three weeks after each dilatation, but required monthly dilatation. Right panel shows the stricture after two years and multiple dilatations. A colonic replacement was performed shortly after the last study.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George D Ferry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_45_30431=[""].join("\n");
var outline_f29_45_30431=null;
